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Abstract 
 
Epigenetic markers are associated with a broad range of disease symptoms, including 
cancer, asthma, metabolic disorders, and various reproductive conditions. Changes in 
epigenetics status could be induced by environmental exposures such as malnutrition, 
stress, smoking, disease and exposure to air pollutants and organic chemicals. Dietary 
factors were extensively acknowledged to be one of the key environmental essences 
affecting chromatin structure. It can diversify the patterns of DNA methylation and 
histone modifications. The changes may be pathogenic and result in severe 
physiological consequences, particularly if the exposure occurs during critical window of 
development. This is potentially attributable to the property of epigenetic activities, 
which occurs not only in somatic and mitotic cells, but also inherited meiotically, 
meaning that the changes are carried over generations [1, 2]. Therefore, maternal 
dietary factors may profoundly characterize the phenotype of subsequent generations 
and consequently contribute to the early onset of chronic disease and metabolic 
disorder [3]. 
 
Sustained high fat feeding leads to obesity and metabolic syndrome, accompanied by 
low-grade inﬂammation, insulin resistance, and dyslipidemia. In general, the prevalence 
of an inflammatory response is highly associated with obesity incidence, cardiovascular 
diseases, non-alcoholic fatty liver disease (NAFLD) and brain damage. In liver, changes 
caused by low-grade inflammation may later result in progressive disease and fibrosis. 
Early exposure to a fat-enriched diet programs the developmental profile, thus is 
associated with disease susceptibility in subsequent generations. Chronic low-grade 
inflammation, resulting from high fat diet, is activated in the fetal environment and in 
many organs of offspring, including placenta, adipose, liver, vascular system and brain. 
It forms the biological basis for many patho-physiological changes and constitutes risk 
factors for disease development. 
 
Chronic inflammatory disorders were recently identified as one of the major targets of 
dietary-induced epigenetic regulation [4]. Although some transgenerational effects of 
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high dietary fat intake have been shown in a couple of studies linked to certain types of 
epigenetic modulations [5-8]; these modifications and their associated physiological 
consequences resulting from high fat induced-chronic inflammation remain elusive. 
Should the MHF-resulted epigenetic code persist throughout generations, 
characterization in such situations may favor the prediction, early prevention, and 
treatment of non-communicable disease in next few generations [9]. 
 
Many studies using high fat models have consistently demonstrated the incidence of 
such inflammatory reactions. However, the potential contributions of epigenetic 
modifications toward the regulation of inflammatory genes and subsequent physiological 
outcomes have not been fully revealed in the high fat feeding model. Cyclooxygenase-2 
(COX-2) produces prostaglandins that participate in multiple physiological and 
pathological processes, including the activation of inflammatory responses. In addition 
to many of the transcription factors known for years, it was recently suggested that 
COX-2 expression is also subjected to epigenetic modifications, either through histone 
remodeling and/or DNA methylation [10]. Therefore, our study aims to investigate the 
epigenetic mechanisms by which consumption of a high fat diet at different life stages 
influences the inflammatory marker COX-2. 
 
Male Sprague-Dawley rats received a high fat diet at different life stages, including 
maternal (HF/C), post-weaning (C/HF), and lifelong (HF/HF). Liver was collected for 
analysis at 12 weeks of age. Results showed that the high fat diet induced the 
expression of COX-2 mRNA in all three high fat groups. RNA abundance of COX-2 in 
HF/HF was significantly higher than that of HF/C and C/HF. Meanwhile, fatty acid 
composition showed that the proportion of Linoleic acid and Arachidonic acid, as well as 
Δ6Desaturase, were significantly increased in high fat groups, potentially motivating the 
biochemical flow as well as providing reaction substrate for COX-2 catalysis. Genome-
wide methylated DNA immunoprecipitation (MeDIP) showed that DNA hypomethylation 
occurred in an upstream region of the distal promoter and two coding regions of the 
COX-2 gene in all three high fat groups. Site-specific hypomethylation of CpG at 5’ UTR 
(untranslated region) of COX-2 was confirmed with bisulfite sequencing. Using in vitro 
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cloning and Luciferase Reporter assay, this region was identified as a novel enhancer 
that produces durable transcriptional activity. In conclusion, high fat intake during 
different life stages resulted in a varied induction level of COX-2 gene expression. 
Altered DNA methylation at specific gene region, including the 5’UTR enhancer 
sequence, may closely associate with COX-2 gene activation. 
 
This study presented a gene-wide illustration of the diet-epigenome interaction. It also 
provided evidence of high fat diet-induced region-specific hypomethylation in the liver of 
the offspring. Since limited research has been conducted to reveal the epigenetic 
regulation of inflammatory markers by high fat diet, this study will not only outline the 
dietary outcomes on the epigenetic profile of a specific inflammatory gene, but also 
provide insight for future mechanistic investigation and clinical appliance in the area of 
epigenetics. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Environment is a major factor in disease etiology [11, 12]. A large number of 
environmental compounds and toxicants have been shown to promote disease, and are 
independent of DNA sequence alterations [13]. Nutrition is a critical environmental 
factor that is indispensable for an individual’s well-being. Nutrients provide elements 
that are essential for life while sustaining basic and advanced biological functions. 
Macronutrients feed human energy needs and also provide elemental building blocks, 
while micronutrients maintain proper bodily functions on the cellular level. Under-
consumption and overconsumption of certain nutrients is related to an increased health 
risk in both animals and humans, including a higher prevalence of obesity, cancer, 
diabetes, and many other non-communicable diseases. The cumulative knowledge of 
nutrition and other relevant research points to the importance of being aware of one’s 
daily dietary intake.  
 
Non-communicable diseases are initiated through altered gene expression, and are 
followed by the aberrant regulation of cellular signaling pathways and physiological 
behaviors. The traditional understanding of DNA is that it is expressed by reading its 
genetic sequence, which is set in stone during our and our children’s lives. Although the 
genetic code is important, it is now widely accepted that DNA is not the dictator of gene 
expression. Environmental conditions, particularly nutrition, play a role in how DNA 
behaves in our children and ourselves. This is part of the relatively new scientific field of 
epigenetics. The so-called epigenome contains huge amounts of information, and 
engages in activities on top of the genome by commanding genetic activities.  
 
Epigenetic studies offer a new way of investigating the biological roots of common 
diseases. The ability to assess the basis of epigenetic mechanisms has improved 
dramatically in the last few years. It is apparent that epigenetics may hold the key to 
understanding diseases that scientists have thus far struggled to comprehend, including 
metabolic syndrome, cancer, neurodegenerative disorders, asthma, and allergies. Age-
related illnesses, such as Alzheimer’s, are a typical example of how these genes can be 
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turned off and on in a manner that leads to the progression of diseases. Another 
exciting breakthrough involves understanding cancer development. Explaining cancer 
by relying merely on gene mutations is rare and difficult. Researchers thus hope to 
develop drugs that will drive epigenetic changes that will help protect against, or stop, 
diseases. However, using an epigenetic drug to switch on or off certain genes may also 
alter other genes in the process, which makes the development of epigenetic drugs a 
challenging endeavor.  
 
Epigenetic information plays an important role in modifying gene expression and can 
potentially affect long-term health. Programming the epigenetic profile, occurs mainly 
during the early stages of development, and is of critical importance to researchers. 
Obesity, diabetes, cardiovascular disease and hypertension can originate during the 
early stages of life and development, and are associated with epigenetic programming. 
Therefore, perinatal care is imperative for keeping epigenetic changes in check. Doing 
so using a combination of cutting-edge epigenetic knowledge and modern technology 
can be used to leverage contributions to public health, life quality, and to reduce the 
economic burden of disease treatment.  
 
Based on this information and the current knowledge gap, the overall goal of the 
present research was to investigate the effects of early life nutrition on one’s wellbeing 
and disease risk in adult life using epigenetic tools. High fat diets are the predominant 
dietary pattern in the contemporary western world, and have triggered numerous health 
problems, which have drawn the attention of researchers. Therefore, this study intends 
to address the epigenetic regulation of inflammatory reactions, which are a major 
consequence, and the essential basis of, relevant pathogenic physiologies in the high 
fat diet scenario.  
  
  3 
CHAPTER 2. DIET, EPIGENETICS AND INFLAMMATION 
 
Malnutrition during Early Development 
 
Thrifty Phenotype Hypothesis (Developmental Origins of Adult Disease) 
The Developmental Origins of Health and Disease (DOHaD) hypothesis addresses the 
“adverse influences during early development, particularly intrauterine life that can result 
in permanent changes in physiology and metabolism, which increase the risk of disease 
in adulthood” [14]. This was initially proposed in 1992 [15] based on the speculation by 
Barker, et al., that low birth weight infants who survived infancy and childhood could 
face an increased higher risk of coronary heart disease later in adult life [16]. This 
hypothesis has been supported and validated by numerous subsequent studies [17] 
[18-22]. One piece of evidence involves the Dutch famine events during 1944 and 1945. 
During this year, the food supply to a densely populated area was cut off, and affected 
some 4.5 million people. This was a unique event that involved a brief period of intense 
nutritional deprivation in a previously well-nourished population whose nutrition source 
was promptly restored after the famine [23]. Children exposed to in utero famine were 
subsequently well-nourished later in childhood. Several years later, findings from the 
Dutch famine cohort studies provided key proofs that in utero undernutrition lead to 
impaired glucose tolerance and type 2 diabetes, and an increased risk of many other 
diseases such as heart disease, obesity, and cancer [24-26]. In addition, they showed 
that dietary intake during pregnancy programs metabolic profiles in the offspring, which 
may account for the aforementioned disease development.  
 
The causality between early life nutrition and well-being in adulthood has become 
increasingly clear in recent years. Altered fetal nutrition has been shown to produce 
many health problems. Using a variety of animal models for maternal malnutrition, such 
as protein restriction and unbalanced macronutrients, it has been demonstrated that 
early life nutritional deprivation reduced placental weight and birth weight [27-30], 
increase blood pressure [31-34], and impair glucose tolerance in the offspring [35-37]. 
In contrast, higher intake of micronutrients during conception was positively associated 
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with birth size and glucose tolerance [38, 39], and negatively associated with blood 
pressure in the offspring [40, 41].  
 
To date, findings from diverse studies using maternal models have led to a better 
understanding of pathogenic mechanisms and promoted the development of preventive 
approaches, as well as potential therapeutic strategies. The most widely accepted 
theory that underlies the developmental origins of disease is known as maternal 
programming. This is “a process whereby a stimulus or insult during a sensitive or 
critical period has irreversible long-term effects on development” [14]. There are quite a 
few underlying mechanisms responsible for the pathophysiology of fetal programming. 
Fetal nutrition is evidently an important key regulators during programming because 
maternal malnutrition usually fails to support fundamental tissue/organ growth and 
development [41]. One consequence is that essential functions associated with 
gluconeogenesis, lipid metabolism, insulin and cortisol secretion, endothelial function, 
and myogenesis are underperformed, which in turn elevates the risks of diabetes, 
hypertension and hyperlipidemia. [14, 41].   
 
Maternal High Fat (MHF) Model  
Compromised nutritional environment during early development produces both 
immediate health problems in newborns, and leads to continuing consequences during 
adulthood. Significant outcomes were revealed in earlier studies that focused on 
undernourished pregnancies [42-44]. These changes initially caused tissue structural 
modifications, which later led to impaired organ functions and biological systems [45]. 
 
In the last decade, a dietary intake greatly shifted towards the consumption of highly 
accessible fat-enriched foods, combined with poor eating habits. Such dietary patterns 
have contributed to the increased prevalence of chronic diseases. Many studies have 
reported higher incidences of obesity, hyperglycemia, and systemic insulin resistance, 
as well as other metabolic disturbances as a direct result of the prolonged consumption 
of high fat foods [46-48]. More importantly, this both affects individuals who consume 
high fat diets, and also predisposes their descendants to similar illnesses. Mounting 
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evidence revealed in animal studies has demonstrated that perinatal exposure to high 
fat diets profoundly alters the intrauterine environment, and leads to permanent 
phenotypic alterations with adverse outcomes that persist throughout the adulthood of 
the progeny. Multiple aspects of physiological outcomes were manifested, including 
growth problems, learning disorders, and susceptibility to chronic diseases [49] [50, 51]. 
Interestingly, postnatal high fat and carbohydrate challenge [52-54], or upon the addition 
of a drug treatment [55], can aggravate these symptoms. This phenomenon is known as 
the “double hit” hypothesis.  
 
Inflammation: a Patho-Physiological Basis for Compromised Health  
Inflammation is a part of the natural defense system that the body maintains against 
injury and disease. Inflammation is a response to environmental stimuli that instantly 
triggers a series of physiological reactions and non-specific immune responses such as 
increased blood flow, cellular metabolism, vasodilatation and fluid influx [56]. Moreover, 
chronic low-grade inflammation is often linked to disease and long-term adverse 
consequences, and is inevitably associated with the pathogenesis of NAFLD/NASH [57], 
cardiovascular diseases [58], renal failure [59], nervous system disorders [60], aging 
[61], diabetes [62] and several types of cancer [63]. This type of inflammatory response 
is commonly observed in obese individuals and in populations with sustained high fat 
intake. It is now know that over consumption of high fat foods before or during 
pregnancy also affects the inflammatory response of the next generation, in a tissue-
specific and in a life stage-dependent manner. 
 
The overconsumption of fat before or during pregnancy results in an unfavorable 
intrauterine milieu. This means that the concentration of energy, hormones, and blood 
supply are suboptimal, and this can lead to abnormal fetal growth and development [50, 
64-67]. Multiple physiological outcomes related to inflammation and early life exposure 
to high fat diet are described below.  
 
Adiposity 
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Earlier studies have suggested the central and enabling role of inflammation in the 
process of cell proliferation, also that it promotes adipogenesis, and simultaneously 
represses myogenesis [68, 69]. Increasing the adiposity capacity allows inflammatory 
signals to generate additional storage space, which constitutes a risk factor for obesity. 
Pro-inflammatory factors, including IL-6, MCP-1 and TNF-α, are closely associated with 
body fat deposits [70-73]. Certain cytokines, such as IL-6, are known to have a 
characteristic tissue-specific function in the process of energy mobilization. In skeletal 
muscle, exogenous IL-6 treatment increased fatty acid oxidation [74, 75] and glucose 
uptake [75]. By contrast, adipose-tissue-derived IL-6 and TNF-α promoted the 
development of insulin resistance in both adipose tissue [76], and skeletal muscle [74, 
77]. Consequently, the above information shows that that maintaining careful control of 
inflammatory response in both circulatory and peripheral tissues is vital for maintaining 
normal physiological functions. 
 
Some studies show that MHF diets result in increased body fat composition [66, 78], 
and elevated growth curve for the offspring [50, 79, 80]. MHF exposure increases 
adiposity [81, 82], promotes adipocyte hypertrophy [66], and is accompanied by a 
decrease of lean body mass [83]. The unpublished data suggests that consuming a high 
fat diet throughout pregnancy and lactation induces mRNA expression of IL-6 and IL-1β 
in adipose tissue of the offspring. The programming of these pro-inflammatory cytokines 
in the adipocytes can contribute to the growing adiposity capacity and excessive body 
weight gain. Additionally, other studies have pointed out that undesired, but normal 
physiological changes due to either high fat [64, 79, 84], or high sucrose challenge [50], 
can be enhanced when the offspring are receiving MHF. The role of systemic 
inflammation in adiposity might account for such phenomena. More importantly, MHF 
can induce inflammatory responses in tissues including, but not limited to, the adipose 
tissue. This will be discussed below. 
 
Cardiovascular Disease 
Biomarkers of Low-grade systemic inflammation, specifically CRP, IL-6 and TNF-α, are 
intimately associated with endothelial dysfunction, carotid artery remodeling, and 
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vascular stiffness [85, 86]. Furthermore, endothelial dysfunction and insulin resistance 
are derived from elevated inflammation [87],  and may contribute to the overall 
progression of hypertension [88, 89], which subsequently leads to renal malfunction [90]. 
Chronic inflammation, in the context of atherosclerosis, also contributes to the lesion 
initiation, progression and ultimately clinical complications [91].  
 
Several animal models that used a fat-rich diet throughout pregnancy and suckling have 
suggested that endothelial and arterial vascular function were compromised in the 
offspring to the extent that blood pressure increased up to a level that impaired 
cardiovascular and renal function [66, 92-97]. Recent evidence supports the hypothesis 
that MHF produces hypertension. However, it appears to develop in an age-dependent 
manner [98]. Chronic inflammatory reactions are potentially responsible for this effect, 
given that increased levels of IL-1β and TNF-α in both the circulatory system and 
arterial walls were detected in the offspring of high fat-fed dams [99, 100]. Nevertheless, 
possibilities that include other contributing factors cannot be excluded. It thus appears 
to be the case that MHF-induced systemic inflammation can have a cumulative and long 
lasting effect, if one consider the time required to eventually reach the clinical 
manifestation.   
 
Brain Damage 
In addition to the relevant metabolic disorders, excessive fat supplementation during the 
early stages of development also impacts cognitive function in the offspring. Studies 
have shown that MHF can cause hypertrophy by altering glial and microglial reactivity 
[79]. It is known that activation of microglia can provoke the secretion of cytokines IL-1β, 
IL-6 and TNF-α [101, 102]. This ultimately results in hypoxic brain injury and acute liver 
failure. In the MHF model, the progeny presented microglial activation and a greater 
reactiveness to LPS, as well as induction of IL-1β [67], and IL-6 in the brain [79, 103]. 
However, the origin of brain cytokines in MHF offspring is still being debated. Some 
studies suggest that a certain level of cytokines pass through the maternal-fetal 
placenta barrier [104], while others indicate the local production in the fetal brain [105]. 
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Taken altogether, these studies propose a new perspective for the underlying 
mechanisms that regulate brain inflammation.  
 
It is not surprising to see heightened inflammatory reactions in the brain, but yet the 
subsequent outcomes deserve a closer attention, as inflammation now is believed to 
significantly partake in the progression of many brain diseases [106, 107]. MHF-induced 
cytokine production affects many compartments of the brain. It produces detrimental 
effects over time and has become a leading cause of undesired functional decline. IL-6 
is typically released from microglia and astrocytes. It is known to accelerate the 
inflammatory progression by actively promoting the production of other relevant 
cytokines, namely IL-1β and TNF-α [108], both of which have been shown to cause 
severe injuries in fetal and postnatal brain [109]. The changes brought about by 
activated inflammation are more likely to be mechanistically associated with long-term 
adverse outcomes. Meanwhile, IL-6 itself is closely associated with cognitive function, 
hypertension, and neurogenesis. The excessive production of IL-6 in the brain was 
shown to impair spatial learning [110], increase hypothalamic-pituitary stimulation [111], 
and reduce neurogenesis in the hippocampus [112]. Consequently, one of the 
mechanisms by which scientists would observe undermined brain functionality in MHF 
offspring involves the up-regulation of cytokines such as IL-1β and IL-6 [103]. These 
outcomes have not yet been fully described in MHF model. Several recent studies 
showed multiple lines of evidences which point out that the offspring exposed to the 
maternal and postnatal high fat diet exhibited difficulties in retaining the previous 
training in a spatial learning tests [79]. Increased susceptibility to deregulated brain 
signaling, including the serotonergic system, can further cause perturbations on 
behavioral patterns [113, 114]. Additional studies should be conducted to define the 
specific events, but it is possible that environmental challenges, disease and aging 
could induce these subjects to underperform in comparison with peers.   
 
Hepatic Energy Mobilization 
MHF has a steatogenic and fibrogenic effect in the liver, but does not necessarily cause 
hepatic lipid accumulation [115, 116]. However, intrauterine exposure to high fat diets is 
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believed to program the hepatic metabolic patterns, and contributes to NAFLD 
progression in the offspring. Severe fat accumulation in liver tissue occurs when a post-
weaning high fat diet is administered, compared with postnatal high fat feeding alone 
[84].  
 
Several animal studies have reported that perinatal exposure to a high fat diet triggers 
the induction of inflammatory markers in the liver. For instance, in a lactating high fat 
mouse model the inflammatory markers IL-6 and TNF-α were significantly induced [115]. 
Another study using a mouse model observed the stimulation of CRP, Mmd2, TNFsf1 
and IL-12b [84]. Some unpublished data concerning rats shows a significant induction of 
several other inflammatory markers, including IL-1β, IL-6 and TNF-α, in the liver of MHF 
offspring. Although, the exact reason for the species-specificity or feeding-timing-
dependent response remains unclear, a common hepatic inflammatory effect in 
response to MHF was observed.   
 
Inflammation triggered by MHF disturbs lipid and glucose metabolism in the offspring, 
and is likely to result in fatty liver disease. For instance, MHF-induced increase of 
circulating TNF-α constitutes a risk factors for fatty liver development [99]. Adipocyte 
overexpression of TNF-α has been shown to drive local lipolysis and  produce free fatty 
acids [117], which consequently enhances fat mobilization in other tissues, including the 
liver [118]. This phenomenon was indeed observed in the MHF model, and increased 
plasma glycerol in the fetus, which suggests up-regulated lipolysis and thus increases in 
hepatic fat deposits [65]. Meanwhile, another study observed increased hepatic lipid 
synthesis and fat accumulation as results of intraperitoneal injection of TNF-α or LPS 
that induced TNF-α [117]. Thus, it is possible that circulating TNF-α, regardless of the 
stimulus, is involved to some extent in the master signaling mechanism for energy 
mobilization throughout the body. On the other hand, local activation of inflammatory 
cytokines in liver tissue, including IL-1β, IL-6 and TNF-α, often worsen insulin signaling, 
and also stimulate of gluconeogenesis and lipid synthesis [119]. These phenomena 
have been found recently in this particular MHF model. Reduced hepatic insulin 
sensitivity in MHF offspring was indicated by the reduced expression of IRS in the liver 
  10 
[115]. Gluconeogenesis is a pathway that helps to maintain plasma glucose, particularly 
during periods of starvation. This pathway was also programmed by MHF, and exhibits 
a significant up-regulation of hepatic Pck1 and G6Pase in the liver [65, 80]. Previous 
research has shown that overexpression of Pck1 is closely associated with 
hyperglycemia and the progression of type 2 diabetes [120]. As a consequence, 
increased liver weight and glycogen content were reported in a follow-up study in the 
offspring of this model [78]. Furthermore, hepatic lipid metabolism is affected by an 
MHF diet, as evidenced by the deregulation of genes involved in fatty acid transport and 
synthesis, as well as TAGS synthesis [84]. Given the fact that these physiological 
outcomes can be attributed to multiple changes throughout the entire system, additional 
investigations are necessary to determine whether repression of inflammation in this 
model is an effective approach for attenuating these symptoms.  
 
More interestingly, fatty acid composition in neonatal liver is modified by MHF, and may 
partially account for the activated inflammatory response. This was exhibited together 
with a decrease on DHA [83] and EPA, along with an increased proportion of oleate, 
linoleate and arachidonate in the overall pool of both TG and FFA [121]. DHA provides 
protection for the cardiovascular system against coronary disease [122], and down-
regulates many inflammatory mediators [123]. Arachidonic acid is a second messenger 
for inflammatory signaling, and actively participates in the inflammatory response and its 
associated physiological changes [123]. Hence, it appears that the elevated n-6:n-3 
ratio in the liver can create a susceptible and enriched environment for inducing the 
chain of inflammatory reactions. 
 
Placental Dysfunction 
Placenta, the primary organ of the maternal-fetal interface, and transports nutrients from 
the mother to the fetus, and is the focus of attention during fetal development. Impaired 
functionality of the placenta is one of the major causes of fetal disease. The 
maintenance of placental normal function during fetal growth eliminates the 
predisposition to preeclampsia [124], preterm labor [125], and stillbirth [126]. Moreover, 
perinatal high fat intake impairs the fetal environment, triggering placental inflammation 
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and its associated complications [127]. More particularly, mRNA expression of pro-
inflammatory cytokines IL-1β, MCP-1 and inflammatory mediator TLR4, are induced in 
the placenta of high fat-fed mothers [128]. Excessive expression of IL-1β and TNF-α 
has been shown to be associated with preeclampsia [129], and TLR4 is associated with 
preterm delivery [130]. Increased placental inflammation is evident, such that 
compromised placental functions, such as decreased blood flow on the fetal side [128, 
131], may result in stillbirth. Unfortunately, a verifiable molecular mechanism for a 
causal relationship between placental inflammation and disturbed utero-placental 
hemodynamics remains elusive. Current data have suggested that these outcomes, if 
any, are independent of NHF feeding, but it has been confirmed that a high fat diet will 
certainly aggravate the chemically induced preeclampsia [132]. 
 
The fetal consequences of increases in maternal circulating cytokines and placental 
inflammation remain elusive. It is easy to observe the increased inflammation in fetal 
circulatory system, liver and brain that follow the consumption of a NHF diet [65, 133]. 
However, it is difficult to pinpoint the origin of these wandering cytokines, given that 
bidirectional transfer of pro-inflammatory cytokines is barely detectable in a normal term 
placenta [104, 134]. Indeed, there is evidence showing that induced cytokines in the 
placenta do not necessarily cross the placental barrier, which has an impact on fetal 
inflammatory status [105], despite the altered permeability due to placental inflammation 
[135]. Therefore, investigations of the transgenerational impact of up-regulated maternal 
cytokines and the fetal origins of inflammation in this model are expected to have 
clinical value and allow for the early prevention and development of therapeutic 
treatment. 
  
State of the Art Research in Epigenetics 
 
Basis of Epigenetics 
Epigenetics is defined as the alterations in gene expression in the absence of 
underlying changes in genetic information [136]. It must be heritable from cell to cell, 
hence through cell lineage development or even transgenerationally from parent to 
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offspring to grand-offspring [1]. Epigenetic mechanisms facilitate the understanding of 
how environmental factors can alter the phenotypic phenomenon without changing DNA 
sequence, and hence the origin of some diseases that are not readily explicable in 
terms of conventional genetic defects.  
 
The study of epigenetics began 70 years ago, and has continued to evolve since then. It 
initially explained the basic process that multicellular organisms reserved for cell 
differentiation, which involves a non-genetic factor that guides cell division and fate 
regardless of the identical genetic code shared throughout one’s system. Classic 
biological actions defined within the realm of epigenetics includes enzymatic 
methylation of cytosine bases, also known as DNA methylation, post-translational 
modifications of certain amino acid residues on histone tails or histone modifications, 
nucleosome positioning, non-coding RNAs, and transcription factor regulatory networks 
[137].  
 
DNA Methylation 
DNA is usually methylated at the carbon-5 position of cytosine that presents in 5’-CpG-3’ 
dinucleotides [138]. CpG islands are the regions of more than 500 base pairs in size 
and with GC content above 55%. It is highly conserved throughout evolution, because 
they are normally kept free of methylation [139]. These stretches of DNA are usually 
located at promoter regions and cause stable heritable transcriptional silencing. DNA 
methylation is primarily a stable repressive marker, yet its regulation is more dynamic 
than what was once believed, and it can be actively removed at specific loci as well as 
genome-wide during development [140]. 
 
DNA methylation usually, but not always inhibits gene transcription, usually but not 
always depending on the position of the methylation change relative to the position of 
the transcription start site [141]. Four DNA methyltransferase (DNMTs), namely DNMT1, 
DNMT2, DNMT3A and 3B have been found to mediate DNA methylation but perform 
different functions [142]. Particularly, DNMT1 maintains the basic needs of DNA 
methylation, copying the pattern from parental strand to the newly replicated strand 
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during cell division, whereas DNMT3A and 3B promote the de novo DNA methylation 
[142].  
 
Histone Modifications 
Unlike DNA methylation, histone tails can be modified in multiple ways as is the case 
with acetylation, methylation and phosphorylation [143]. Acetylation of histones at lysine 
residues is catalyzed by histone acetyltransferases (HATs), and is associated with the 
activation of gene transcription. Deacetylation of histones is associated with the 
silencing of transcription, and is catalyzed by histone deacetylases (HDACs) [144]. 
Overall, the acetylation of histones marks active transcriptionally competent regions, 
while hypoacetylated histones are found in transcriptionally inactive euchromatic or 
heterochromatic regions. Histone methylation regulates gene transcription depending 
on the site of modification. Methylation of lysine 9 on the N terminus of histone H3 
(H3K9Me) is typically a hallmark of silent DNA and is globally distributed throughout 
heterochromatic regions such as centromeres and telomeres [145]. However, 
methylation of lysine 4 of histone 3 (H3K4Me) activates gene transcription and is 
primarily found in promoter regions [145]. Lysine can be modified by mono-, di- and 
trimethylation. The enormous variation is thus likely to result in a diversity of possible 
combinations of different modifications.  
 
Epigenetic Interactions 
There is emerging evidence that there are connections between DNA methylation and 
histone modifications [146]. Eukaryotic DNA is greatly associated with histone proteins, 
and forms a highly ordered and condensed DNA-protein complex termed chromatin 
[144]. DNA methylation influences both histone modifications and overall chromatin 
structure by guiding the histone deacetylation of certain residues [147], DNA 
methylation is intimately connected with histone modifications [148]. DNMTs as well as 
three protein complexes that contain methyl-CpG-binding domain [149], were found to 
bind HDACs, which represses gene transcription [150]. Interestingly, it was once 
believed that histone modification was secondary to DNA methylation. Recent studies 
have revealed that histone modifications can take the initiative in chromatin 
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conformation by assisting the process of DNA methylation [146, 151, 152]. There 
appears to be a close relationship between DNA methylation and histone modulations, 
but many questions concerning the details of such interactions remain to be answered.  
 
Other than these modifications, RNA in various forms, including antisense transcripts, 
noncoding RNAs, or RNA interference (RNAi), is also capable of triggering the 
transcriptional silencing of genes by aiding histone modification and DNA methylation 
[148].  
 
Developmental Programming of Epigenome 
Mammalian reproduction involves a single-cell zygote giving rise to a complex living 
organism with a large variety of cell types. These highly diversified cellular phenotypes 
are produced from the identical genomic sequence by mediating the subset of genes 
expressed in each cell type. Thus, cellular differentiation, and tissue and organ 
formation, rely largely on the process of extensive erasure and the precise 
establishment of lineage-specific epigenetic markers, which are termed epigenetic 
reprogramming. The Epigenome is re-established at fertilization, beginning with the 
initial wide-ranging loss of epigenetic marks in the zygote and early embryo, followed by 
the resetting of DNA methyl marks during many stages of cell division [153].  
 
Developmental plasticity makes the reprogramming process highly susceptible to fetal 
and early life environmental exposure due to developmental plasticity. Epigenetic 
modifications, such as DNA methylation, are substantially sensitive to perturbation at 
the earliest stages of development, and most likely resulting in lifelong and possibly 
transgenerational effects. Chromatin states that arise during this period can further 
affect the propensity to subsequent epigenetic change. This is evident in the 
predisposition of polycomb-repressive complex occupied genes in stem cells to acquire 
DNA methylation abnormalities in aging and cancer [154-157].  
 
The “developmental origins of adult disease” hypothesis posits gene-environment 
interactions that result in long-lasting effects, and suggests epigenetic inheritance as a 
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prime mechanism. During the early stages of development, a folate (methyl donor) 
deficient diet reduces the methylation of offspring on a whole-genome scale [158]. 
Indeed, rodents are often used to study the subject of developmental programming. 
This model has gained recognition, mostly by acknowledging that in utero malnutrition 
not only affects gene expression through epigenetic profile editing. This is the case 
because the progeny responds to environmental chemicals as well as ultimate adult 
phenotype does [159].  At this point, limited information is available from human studies, 
although DNA methylation appears to be the culprit for imprinting gene regulation when 
early life nutrition was manipulated [160].  
 
Transgenerational Inheritance 
Epigenetic marks in somatic cell lineages can be transmitted to daughter cells over the 
lifespan of an individual, while marks established in germ cell lineage can be transmitted 
to subsequent generations. Determining the transgenerational effects of epigenetic 
mechanism requires at least three generations after the exposure. Mounting evidence 
has demonstrated the apparent transmission of environmental insult across generations, 
although this remains highly controversial [161].  
 
Environmentally induced germline epigenetic modifications occur during the DNA 
demethylation and remethylation period [162]. Certain types of chemical environmental 
exposures have been shown to promote the epigenetic transgenerational inheritance of 
adult onset disease, and the transgenerational epigenetic changes can be used as 
biomarkers of exposure and disease [163]. Several studies of the transgenerational 
effects of high dietary fat intake have been shown to be linked to certain types of 
epigenetic modulations [5-8], direct association between these modifications and their 
physiological consequences that result from high fat-induced chronic inflammation 
remain elusive. Given the potential persistence of the trans generational epigenetic 
code, characterization in such situations in MHF model may favor the prediction, early 
prevention, and treatment of non-communicable diseases in the next several 
generations [164]. 
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Epigenetics and Disease 
 
Epigenetic vs Genetic 
Conventionally, it was believed that the inheritable material carried in the primary 
sequence of the DNA double helix was the predominant of the determination of 
variations in the susceptibility and severity of disease. The understanding of how 
germline genetic variations influence disease development was assisted by 
technological advances and was expanded in many genome-wide association studies 
[165-167]. Changes in the DNA sequence drastically interrupts gene expression, and 
can lead to the genesis and progression of several diseases [166]. However, these 
studies also support the idea that common genetic variants alone tend not to identify the 
causal loci of complex diseases, and do not dictate individual disease risk [165]. 
Fundamental modification of the genome, also known as epigenetics, thus becomes a 
determinant of disease risk and etiology [168, 169], because it allows an individual 
system to modify how the genome is read in response to environment cues [168, 170].  
 
Epigenetic events are inheritable and can be long-lasting, just like genetic information. 
Nevertheless, epigenetics differs from genetic changes in a small number of unique 
characteristics. First, it does not involve alterations of the DNA sequence and is 
reversible in principle [171]; secondly, epigenetic events are subject to reprogramming 
by endogenous or exogenous factors throughout the life span in a continuous editing 
process [172-176]. These unique features allowed of alternative explanations of disease 
variability to thrive, including diseases that cannot be fully explained by genetic 
variations and changes.  
 
Environmental Epigenetics and Disease Etiology 
Environmental epigenetics refers to the phenomenon by which epigenetics can explain 
the variability in the risk and severity of environmental diseases. The external 
environment, which includes lifestyle factors that are linked to stress, abuse, addiction, 
alcoholism and metabolic changes, are comprised in such a concept [177]. Particular 
environmental factors, such as endocrine disruptors, infectious pathogens, outdoor 
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pollutants, indoor allergens, and heavy metals, have been shown to yield epigenetic 
changes [177].  
 
Environmental factors can trigger complex diseases, including cancer, cardiovascular 
disease, stroke, pulmonary diseases, asthma, obesity, and neurodegenerative disorders 
[178-181]. More importantly, changes in the epigenetic status due to early-life 
reprogramming or experiences during adult life have shown a strong correlation with the 
severity and progression of these diseases [177]. Therefore, the behaviors of the 
epigenetic code canbe expected to indicate exposure to environmental toxins, as well 
as risk and the progression of diseases. Current investigations are focusing on the 
mechanistic regulation of epigenetic events, in order to promote a better understanding 
of the etiology of environmental disease and future development of preventive 
strategies.  
 
Disruption of either the sequence or composition of the epigenetically regulated genes 
that result in their aberrant expression, are considered to be the fundamental 
mechanism underlying abnormal differentiation and disease development. Epigenetic 
factors have been determined to be involved in the pathogenesis of many types of 
cancer and common multifactorial disorders [182]. Aberrant de novo methylation of CpG 
islands is a hallmark of human cancers and can be found early during carcinogenesis 
[183]. Functional epigenetics changes have been observed in obesity [184], diabetes 
[185], cardiovascular disease [186] and the constellation of abnormalities known as 
metabolic syndrome [187]. Neurological disorders, cancer, reproductive conditions, and 
the pathogenesis of asthma have been suggested by emerging evidences that are 
attributed to epigenetic alterations [188].  
 
Epigenetic changes are sensitive readouts of the consequences of acute and chronic 
exposures to environmental factors. They greatly rely on dose, duration, and life-stage 
at the time of exposure. More particularly, intense effects are usually found during the 
susceptible window of fetal development [177], thus exposure to environmental factors 
during a certain developmental stage will strongly influence disease etiology. During this 
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time window, differentiation of cells and organ systems are susceptible to programming. 
Consequentially, altered programming and gene expression due to environmental 
factors can lead to abnormal physiology and disease in adult life [162]. Therefore, it is 
reasonable to assume that environmental factors predispose phenotypic changes or 
disease progression, and this is not limited only to the individual exposed, but also 
includes subsequent generations. Normally, exposure to mild environmental factors 
such as nutrients, toxicants, or endocrine disruptors, are insufficient in and of 
themselves to produce genetic mutations, but can produce alterations in the epigenome, 
which are known as epimutations [162]. These epimutations can potentially reside in the 
germline of individuals exposed and become inheritable cross generations, and lead to 
the early onset of certain types of diseases. 
 
Epigenetics and Inflammation 
Inflammatory signaling has recently been identified as an epigenetic mediator [189]. It 
has been suggested that histone acetylation is closely associated with inflammation 
[190-192]. The pro-inflammatory signaling networks of IL-1β, LPS, and TNF-α-induced 
pathways may impact histone modifications through the activation of HDAC1 by 
ubiquitination and proteosomal degradation [193, 194]. On the other hand, a growing 
body of evidence has shown the power of epigenetics at regulating inflammatory genes, 
the incidence of which may eventually result in multiple physiological consequences 
[195]. For example, the addition of HDAC inhibitor can reduce the expression of pro-
inflammatory mediators in glial cells, and has the potential to result in improved neural 
cell function and survival [196]. Meanwhile, a histone acetyltransferase (HAT) inhibitor 
can reduce the acetylation of NF-κB, which in turn suppresses the expression of 
cytokines in microglial cells and prevents neuronal cell death [197]. Furthermore, a few 
of chromatin-remodeling proteins including Brg1, Brm [198] and TET1 [199], are thought 
to participate in pro-inflammatory cytokine gene regulation of IL-1, IL-6 and MCP-1, 
possibly through increased activation of histone modifications. However, this leads to 
the progression of NASH [198]. Unfortunately, evidence for epigenetic programming of 
the inflammatory response by intrauterine environment is scarce, even so for the MHF 
model. Although chromatin remodeling in this model has been confirmed for certain 
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functional genes [80, 200], no indication of inflammatory marker programming has been 
revealed in any studies involving MHF. Nevertheless, given the reciprocal interaction 
between epigenetics and inflammation, MHF-induced chronic inflammation has the 
potential to shape the epigenetic profile of other functional genes, and the expression of 
inflammatory genes themselves are susceptible to epigenetic modulation. More 
investigations are therefore needed to explore the epigenetic mechanisms and the 
development of cutting edge therapeutic approaches.  
 
Application of Epigenetics in Pharmacology 
Epigenetic changes are intertwined with a variety of diseases. Manipulation of the 
epigenetic status is thus likely to expand the array of its applications [201]. Indeed, 
epigenetic therapy is believed to be a new development in pharmacology, by virtue of 
attempting to correct epigenetic defects, including changes in DNA methylation and/or 
histone modulations. It is a medical strategy with great potential, since epigenetic 
defects tend to be more reversible than genetic defects when using pharmacological 
interventions [202-204]. So far, two clusters of drugs have been developed; one aims to 
inhibit DNA methyltransferases (DNMT), and results in the inhibition of DNA methylation, 
which blocks one type of causative mechanisms of cancer where tumor suppressor 
genes are hypermethylated. The other major group targets the inhibition of HDACs, 
which reduces histone deacetylation which may serve to mediate the anticancer effects 
of these drugs. Promising results have been observed in drug trials for cancer treatment. 
More importantly, epigenetic drugs may be capable of preventing disease, in addition to 
the therapeutic agents [205]. Epigenetic therapy has limitations because both DNMT 
and HDAC inhibitors lack specificity, which can accelerate tumor progression in certain 
cases [206]. A variety of molecules are involved in epigenetic mechanisms, and other 
potential targets are plausible for drug development purpose.   
 
Interaction between Nutrition and Epigenetics 
 
Dietary Effects on Epigenetic Profile 
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Many environmental factors can interfere with the epigenetic status and produce either 
transient or permanent alterations of chromatin structure. Environmental factors, 
smoking, chemical exposure, etc., together with eating patterns, can profoundly affect 
biological processes, including oxidative stress and inflammation, which will directly or 
indirectly shape the state of the epigenome. Epigenetic mechanisms have recently been 
used more frequently used to describe environmental effects on phenotypes, 
particularly the nutritional status.  
 
In the 1940s, nutrient supply was initially recognized as an authoritative element, whose 
intensity produces long-lasting physiological phenomenon that modify the epigenetic 
code during a critical developmental window [160, 207]. The biological role of nutrition in 
the process of phenotypic differentiation has been documented in honeybees [208], and 
agouti mice [209], and both of them involve DNA methylation [210]. Folate is a typical 
nutrient that is often used when studying methylation regulation. Folate is a major 
source of the methyl groups for DNA and histones [211]. Moreover, imbalanced dietary 
intake of folate is associated with methylation changes and consequently gene 
deregulation, and subsequently increased disease risk [212, 213].  
 
Food intake can also manipulate the epigenetic code by integrating miRNA into the 
metabolic activities of consumers, with little nutrient content relevance. It was 
determined that a plant-origin microRNAs, MIR168a, binds to the coding region of 
mammalian genes and decreased protein production [214]. A lot more investigations 
are required to confirm this phenomenon.  
 
Developmental Plasticity and Nutrition 
Developmental plasticity should ideally allow the organism to monitor its growth process 
in an attempt to promote phenotypic changes that better equip it to fit with the 
environment. However, in face of an excessive or deficient nutrient supply during the 
early stages of life, the progeny are more likely to be programed with greater limitations, 
which undermine their defensive capacity against postnatal environmental challenges. 
They may consequently experience abnormalities in terms of body size, growth rate, 
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tissue distribution, metabolic profile, and hormonal imbalance and underperformed 
intellectually [215, 216]. It is now generally accepted that MHF is an unfavorable 
intrauterine environment that is closely associated with the development of metabolic 
syndrome and an increased risk of an obese phenotype developing in the offspring 
[217]. However, researchers are only beginning to understand the basis of mechanism 
that leads to the initiation of those signaling cascades, which in turn produce structural 
and functional cellular changes, physiological damage, and ultimately chronic diseases. 
Evidence has shown that maternal environment affects gene transcription, partially 
through epigenetic modulation, including DNA methylation, multiple forms of histone 
modifications [218] and microRNA [219, 220]. Therefore, the concept of epigenetic 
regulation can serve as a critical link between maternal diet and progeny phenotype, 
which consequently supports the DOHaD hypothesis.  
 
High Fat Diet and Epigenetics 
High fat diets impact greatly the epigenetic structure, such as the intensity of DNA 
methylation of genes that were highly involved in pathophysiological process. In 
general, metabolic and cell cycle relevant genes in liver tissue are the subject of DNA 
methylation regulation. For instance, methylation intensity at CpG sites of Esr1 [221], 
stearoyl-CoA desaturase 1 (Scd1) [222], promoter of glucokinase, pyruvate kinase [223] 
and MTTP [224], was differentially regulated by high fat-diets. Deregulation of these 
genes is primarily associated with aberrant hepatic lipid and glucose metabolism, and 
result in the development of various types of non-communicable diseases, including 
fatty liver disease and obesity. In addition, altered DNA methylation patterns of cell 
cycle controlled gene Cdkn1a [225], and the growth hormone secretagogue receptor 
[226], were reported in a MHF model, which indicates the transgenerational epigenetic 
effects of high fat diets. DNA methylation induced by a high fat diet elicits broad effects 
in other tissues besides the liver. For example, the CpG sites of FASN and Leptin in 
adipose tissue [227], as well as for the brain μ-opioid receptor [228], tyrosine 
hydroxylase and the dopamine transporter [228], leptin [229], and melanocortin-4 
receptor (mcr4)[230], were reported to be differentially methylated by high fat diet. A 
significant correlation between DNA methylation and gene expression has been 
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validated in several of these studies, which indicates that consuming a high fat diet 
affects gene regulation by altering the DNA methylation status of gene. The effects of 
high fat diets on the global DNA methylation on the whole-genome level have been 
rarely investigated.  
 
Conclusion 
 
The understanding of the epigenetic-based mechanisms for inflammation activation in 
the high fat model is insufficient to explain the constellation of body responses to the 
environment. Previous research has shown that in utero exposure to high fat diets 
programs the increased susceptibility to chronic diseases during development and 
growth. There appears to be a causal relationship between low-grade chronic 
inflammation and such adverse outcomes. However, it is difficult to pinpoint a single 
causative mechanism, or even draw out a conclusion given the essential role that the 
inflammatory response plays in many cellular and physiological processes. Epigenetic 
mechanisms are associated with a myriad of developmental diseases. It is widely 
recognized as a new therapeutic approach nowadays, and unraveling the epigenetic 
regulation of inflammatory markers in a high fat model can assist disease prevention 
and treatment in both the current generation and in subsequent generations as well.   
 
Project Overview 
 
Background 
Consumption of high fat increases the risk of obesity and metabolic syndrome, both of 
which were suggested to be closely associated with a low-grade chronic inflammation. It 
has been shown that high fat feeding specifically increased proinflammatory signaling, 
including Cyclooxygenase (COX) -2 expression, in a diet-induced obesity mice model 
[231]. However, the molecular mechanisms regarding epigenetic modifications on COX-
2 in this model remains to be elucidated. The COX family comprises two isoforms, 1 
and 2, sharing significant sequence homology and catalytic activity. COX-1 is 
constitutively expressed to produce prostaglandins (PG) for maintaining homeostatic 
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functions, whereas COX-2 requires additional extracellular and/or intracellular stimuli, 
including exogenous and endogenous arachidonic acid [232, 233]. The COX enzymes 
catalyze the conversion of arachidonic acid to prostaglandins, from which the substrate 
for cell specific prostaglandin and thromboxane synthases are produced [234]. 
Prostaglandins are involved in numerous physiological and pathological processes 
including inflammation, and they are rapidly increased by COX-2 in the scenario of 
inflammation [235]. Induction of COX-2 is transient, with a rapid return to baseline within 
hours following treatment [236]. Therefore, expression of COX-2 is strictly regulated and 
it is only markedly induced during inflammation. The nutritional environment alters 
epigenetic profiles through DNA methylation and histone code, and thereby affects gene 
transcription, intracellular signaling and ultimately the development of disease. Although 
it is known that high fat feeding triggers an inflammatory response including COX-2, 
there is little knowledge of the epigenetic mechanisms involved. Our study here propose 
a connection between high fat diet, COX-2 transcription and epigenetic modifications, 
which has never been tested in previous research. By conducting the present research, 
it hopes to improve the understanding of epigenetic-related COX-2 gene regulation. 
 
Objective 
The objective of this study is to identify the molecular mechanisms involved in high fat –
induced COX-2 gene expression.  
 
Hypothesis 
High fat diet induces inflammatory marker COX-2 expression associated with epigenetic 
modifications.  
 
Specific Aims  
1. Characterize the physiological outcomes and COX-2 response to high fat feeding 
at different life stage  
2. Determine if COX-2 expression is associated with epigenetic modifications, 
including DNA methylation and histone modifications. 
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3. Identify if there is any regulatory element on COX-2 gene that responses to high 
fat signal.  
 
Discussion 
In Chapter 3, 4 and 5, this study presented several lines of evidence to demonstrate 
that high fat feeding (maternal, HF/C; post-weaning, C/HF and life-long, HF/HF) affects 
physiological and pathological phenomena in the liver of pups. The resutls revealed that 
COX-2 gene expression increased in pups’ liver along with multi-regional DNA 
hypomethylation in high fat diet. 5’UTR hypomethylated region was further identified 
and characterized as an enhancer element that potentially contributes to COX-2 gene 
activation.  
 
Prolonged high fat dietary feeding instigates an inflammatory response, following which 
a variety of proteins, including COX-2, can be significantly induced. Understanding how 
dietary components regulate gene expression at epigenetic level provides a novel 
insight that connects environment and disease predisposition. Following the completion 
of the present study, a link between increased hepatic COX-2 seen with high fat diet 
feeding with specific epigenetic modification will be elucidated.  
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CHAPTER 3. HIGH FAT DIET INDUCES COX-2 GENE EXPRESSION 
 
Abstract 
 
Sustained high fat feeding leads to obesity and metabolic syndrome, accompanied by 
low-grade chronic inﬂammation, insulin resistance, and dyslipidemia. Changes caused 
by low-grade inflammation in the liver can result in the progression of disease and 
fibrosis. COX-2 is an enzyme that produces prostaglandins, which participate in multiple 
physiological and pathological processes, including the activation of inflammatory 
responses. Male Sprague-Dawley rats received a high fat diet during different life 
stages, including maternal (HF/C), post-weaning (C/HF), and lifelong (HF/HF). Liver 
samples were collected for analysis at 12 weeks of age. Total fat accumulation and liver 
damage evaluation were significantly higher in HF/HF than in the rest of the treatment 
groups. Analysis by PCR of the expression of COX-2 mRNA showed an induction in all 
of the high fat diet groups, especially in the HF/HF group, which doubled the induction 
fold of HF/C and C/HF. Meanwhile, analysis of fatty acid composition showed that 
proportion of both Arachidonic acid and Δ6-Desaturase, which produces Arachidonic 
acid, significantly increased in the high fat groups, which may have motivated the 
biochemical flow as well as provided the reaction substrate for COX-2 catalysis. In 
conclusion, induction of COX-2 gene expression in response to a high fat diet is 
associated with the period of exposure.  
 
Introduction 
 
Modern western diets are rich in fat content. Prolonged consumption of high fat diets is 
the causal agent of numerous health problems, including promotion of hepatic 
triglyceride accumulation, insulin resistance, oxidative damage, and chronic low-grade 
inflammation, which leads to the progression of liver disease and fibrosis [237, 238]. A 
murine study showed that consumption of a high fat diet changed liver morphology, 
which created a permissive environment for colon cancer metastasis [239]. A high fat 
diet can also change cellular membrane protein composition [240], elevate the 
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abundance of pro-inflammatory molecules, and give rise to hepatic insulin resistance 
[241].  
 
Induced pro-inflammatory signaling is usually signified by activated expression of 
certain genes, such as Interleukin family members and COX-2 [116, 242]. Activated 
COX-2, rather than COX-1, is persistently found during the activation of inflammatory 
responses [243]. COX-2 is a key regulatory enzyme involved in the production of 
prostaglandins, which are important in mediating many biological processes, including 
reproduction and immune function. COX-2 actively produces prostaglandins using 
exogenous and endogenous arachidonic acid [233]. This occurs during injuries and 
inflammation in the metabolic steatohepatitis scenario [244]. In addition, overexpression 
of COX-2 is usually associated with inflammatory responses, many types of cancers 
[236], and preterm labor [245].  
 
Exaggerated COX-2 expression has significant tissue-specific consequences: 
accumulation of COX-2-derived prostaglandins initiates a multitude of physiological 
responses, which generally result in fever and pain. However, in the liver, excessive 
expression of COX-2 accounts for the pathogenesis of insulin resistance [246, 247], 
fatty liver disease [246, 248], and hepatocellular carcinoma [249]. This study is 
dedicated to a better comprehension of the pathogenic properties that result from the 
exposure to a high fat diet at different stages of life. Examination will include COX-2 
gene expression and other relevant physiological features.  
 
Materials and Methods 
 
Experimental Design 
Timed-pregnant Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) 
were separated into two dietary groups: either control (C, 16% fat) or high fat diet (HF, 
45% fat) throughout gestation and/or lactation.  Rats were kept individually in standard 
polycarbonate cages in a humidity- and temperature-controlled room on a 12-hour light-
dark cycle, with ad libitum access to food and drinking water.  Body weight and food 
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intake were recorded every three days during gestation. Body weight of the offspring 
and liter size were recorded right after delivery. Twenty-four hours after birth, both 
groups of dams were randomly assigned 10 pups (5 male and 5 female coming from the 
same gestational diet) until weaning at day 21. After weaning, pups from both groups 
were housed individually and exposed to either C or HF diet until they were sacrificed at 
12 weeks of age, generating four groups: C/C, HF/C, C/HF and HF/HF. The left lobe of 
the liver was snap-frozen in liquid nitrogen and stored at -70C until use. We certify that 
all applicable institutional and governmental regulations regarding the ethical use of 
animals were followed during this research (University of Illinois Institutional Animal 
Care and Use Committee approval no. 09112). 
 
Liver Histology  
Frozen liver samples were embedded in Tissue-Tek OCT compound (VWR, Radnor, PA) 
and cut to a thickness of 5 µm in a cryostat at -20°C.  All sections were fixed in 70% 
ethanol and stained with hematoxylin and eosin (H&E) or Oil red O (ORO) solution 
(Newcomer Supply).  Histopathological examination was conducted by the certified 
pathologist. The grading scale used to assess microscopic damage in liver was 0: none, 
1: minimal, 2: mild, 3: moderate, 4: marked and 5: severe.   
 
Biochemical Assays  
Frozen liver samples were ground in liquid nitrogen and homogenized in 0.3 mL saline 
(0.9% w/v NaCl).  Homogenized samples were diluted 5 times with saline.  Twenty 
microliter of the diluted samples were incubated with 20 μL 1% deoxycholate in 37 ºC 
for 5 min and 10 μL of the sample were analyzed using the Thermo Infinity Triglycerides 
Liquid Stable Reagent (Thermo Fisher Scientific, Rockford, IL) and a standard reference 
kit to determine the TAG content (Verichem Laboratories, Providence, RI). The results 
of hepatic TAG were normalized to the amount of total protein in the sample. Serum 
samples were analyzed for circulating TAG using the same method.  
 
Gas Chromatography Analysis of Fatty Acid Content in the Liver   
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Total lipids were extracted from frozen liver tissue (~100 mg) with the method described 
by Bligh and Dyer [250], using chloroform:methanol (1:2 v/v) and 0.15 N acetic acid. 
Each extraction solvent contained 0.05% (w/v) BHT to prevent lipid oxidation during 
extraction. An aliquot of total lipid was spiked with heptadecanoic acid as internal 
standard, dried under nitrogen and derivatized by heating at 95 °C in 3 N methanolic 
HCl (Supelco, Bellefonte, PA) for 40 min. After cooling to room temperature, fatty acid 
methyl esters were extracted with hexane. Samples were injected onto a 5890 Series II 
gas chromatograph (Hewlett-Packard, Palo Alto, CA) equipped with a flame ionization 
detector and a 30 m × 0.32 mm Omegawax 320 column with 0.25 μm film thickness 
(Supelco, Bellefonte, PA). Chromatography conditions used were 180 °C for 5 min, 
followed by a temperature increment of 6 °C per min, and ended with isothermal at 
220 °C for 15 min. Peaksimple software (SRI Instruments, Torrance, CA) was used for 
data collection and integration. Each fatty acid was normalized to the total fat content 
and presented as percentage of total fatty acids. 
 
RNA Isolation and Two-step Real Time Quantitative PCR (qPCR)   
Total RNA samples from tissues and cells were extracted using TRI reagent (Sigma, St. 
Louis, MO).  cDNA was synthesized using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) in a Thermal Cycler (Applied Biosystems) at 
25°C for 10 min, 37°C for 2 hr and 85°C for 5 s.  Real time PCR was then performed 
using SYBR Green fast master mix (Quanta Biosciences, Gaithersburg, MD) in the 
7300 PCR System (Applied Biosystems, Foster City, CA) at 95°C for 10 min, followed 
by 35 cycles of 95°C for 15 s and 60°C for 1 min.  A serial dilution of a sample was used 
as the standard curve to quantify all the samples for relative mRNA expression level.  
Ribosomal protein L7a was used as an internal control. Primers used for qPCR are 
shown in Table 3.4.   
 
Protein Extraction and Western Blotting 
Liver tissues were lysed with 1X Laemmli Buffer [62.5 mmol/L Tris–HCl, pH 6.8, 2% 
SDS, 10% Glycerol v/v, 0.01% Bromophenol blue, 5% 2-mercaptoethanol, 1x protease 
inhibitors (Roche, Indianapolis, IN) and 1x phosphatase inhibitors (Sigma-Aldrich)].  For 
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longer storage, the protein samples were placed in -70 ºC.  Lowry assay was performed 
to determine protein concentration.  Samples containing 30 μg of protein were resolved 
by 10% SDS-PAGE.  A wet transfer protocol was performed to complete the transfer.  A 
PVDF membrane (0.2 μm, Bio-Rad, Hercules, CA) was blocked in 10% milk in TBS/T 
(30 mM Tris base pH 7.6, 200 mM NaCl and 0.1% Tween 20) for one hour at room 
temperature.  The membranes were incubated with antibodies against COX-2 (#4842, 
Cell Signaling Technology, MA) in 10% non-fat dry milk at a 1:1000 dilution at room 
temperature for 3 hours.  SuperSignal West Dura Extended Duration Substrate kit 
(Thermo Scientific, Rockford, IL) was used to detect the signal and the images were 
captured and analyzed by a Chemi Doc XLR system (Bio-Rad).  Actin was used as an 
internal control to normalize the protein data. 
 
Immunofluorescence 
To identify the localization of COX-2 in liver, immunofluorescence staining of COX-2 
was conducted using an Alexa Fluor 647-labeled anti-rabbit secondary antibody (red) 
(Invitrogen). Frozen liver samples were embedded in Tissue-Tek OCT compound (VWR, 
Radnor, PA) and cut to a thickness of 5 µm in a cryostat at -20 °C. The sections were 
fixed in 70% ethanol, permeabilized with 0.1% Triton X-100, blocked with Image-iT FX 
signal enhancer (Invitrogen) for 30 min, incubated with primary antibody COX-2 (1:200, 
cat # 9587S, Abcam) for 2h, followed by an incubation of the secondary antibody (1:200 
dilution) for 45 min in a dark chamber. The samples were counterstained with Hoechst 
33342 (Invitrogen) for 15 min and then washed with PBS.  Coverslip was mounted on 
the sections using Prolong Gold anti-fade reagent (Invitrogen).  Pictures were taken 
using the Zeiss LSM 700 Confocal.  
 
Statistical analysis 
Body weight and food intake were tested using repeated-measures one-way ANOVA. 
The synergistic effects of maternal and postweaning high fat diet were analyzed using 
Two-Way ANOVA [251]. Post-hoc analysis was performed using Fisher’s least 
significant difference (LSD, SAS v. 9.1.2, SAS Institute, Cary, NC) when the P-value of 
interaction of main effects (maternal vs postweaning) was less than 0.15. Individual bars 
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with different letters differ (P<0.05). Significance was set at p<0.05 for all comparisons. 
Individual bars with different letters differ (P<0.05). Correlation between COX2 mRNA 
and COX-2 pre-mRNA or Δ6desaturase mRNA was determined by Spearman's rank 
correlation coefficient analysis (Spearman's rho).  
 
Results 
 
Growth Curve and Calorie Intake 
An overall dietary effect was observed on both growth curve and calorie intake. 
Individual comparison between treatment groups showed that maternal diet did not 
significantly impact body weight gain (Figure 3.1A) nor calorie intake (Figure 3.1B) of 
offspring fed the same diet. However, there was a clear overall separation by post-
weaning diet (Table 3.1). Offspring fed with the high fat diet exhibited a greater increase 
in body weight gain (Figure 3.1A) and calorie consumption (Figure 3.1B) compared to 
that of the control group, regardless of maternal diet.  
 
Liver Histology and Lipid Profile  
H&E and Oil Red O (Figure 3.2) staining were graded individually to evaluate the 
pathological changes corresponding to HF dietary intervention at different life-stages 
(Figure 3.2). Compared to C/C, only life-long high fat feeding (HF/HF) remarkably 
increased the severity of liver damage at the end of 12 weeks. Severe micro-and/or 
micro-hepatocellular vacuolation (Figure 3.3, top) and increased hepatic neutral lipid 
accumulation (Figure 3.4, top) resulted. In contrast to HF/HF, early life stage high fat 
treatment (HF/C) or post-weaning high fat treatment (C/HF) did not lead to severe liver 
damage; post-weaning high fat treatment (C/HF) elevated hepatic fat accumulation 
(Figure 3.4, top) whereas a NHF diet (HF/C) significantly increased circulating TAG in 
comparison to the remaining groups (Figure 3.4, bottom).  
 
Liver Fatty Acid Profile and Associated Enzymes 
Palmitoleic acid (PA, 16:1n-7) content was decreased in post-weaning high fat-exposed 
groups (C/HF, HF/HF), while the content of linoleic acid (LA, 18:2n-6) increased in the 
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C/HF group. Arachidonic acid content (AA, 20:4n-6) was significantly greater in high fat-
treated groups, regardless of the life-period of exposure (Table 3.2). Palmitoleic and 
linoleic acid are fatty acids that have no direct association to COX-2 induction [252], 
however in many circumstances linoleic acid can be converted into arachidonic acid, 
which is the primordial substrate for COX-2 catalysis. To investigate the sources of 
arachidonic acid in the liver of all high fat groups, mRNA expression of both 
Δ6desaturase that converts linoleic to arachidonic acid [253] was measured. HF 
treatment at all life stages increased mRNA expression of Δ6desaturase significantly. 
Therefore, accumulation of arachidonic acid exerted by all high fat diets is due to the 
desaturation reaction actively associated with COX-2 induction.  
 
HF Diet Regulates Gene Expression 
COX-2 mRNA expression was notably increased in all high fat-fed groups (HF/C, C/HF 
and HF/HF) (Figure 3.5). Statistical analysis revealed that compared to C/C, exposure 
to a high fat diet during an early developmental (fetal and suckling) or postnatal period 
significantly induced COX-2 mRNA expression by ~10 fold; Life-long feeding of the high 
fat diet (HF/HF), however, stimulated COX-2 transcription to a remarkably high level, 
which was significantly different than COX-2 levels in both HF/C and C/HF; furthermore, 
COX-2 pre-mRNA, as well as Δ6desaturase mRNA in HF/HF, did not differ from HF/C 
or C/HF, which may be due to the high variation within the groups. Nevertheless, both 
COX-2 pre-mRNA and Δ6desaturase mRNA were positively correlated to COX2 mRNA 
level (Figure 3.7), suggesting a synergistic effect of maternal and post-weaning high fat 
diet on these two genes.  
 
Protein Abundance of COX-2 Increased by High Fat Treatment 
To confirm the protein content of COX-2 in the four treatment groups, both Western blot 
(Figure 3.6) and Immunofluorescence (Figure 3.8) were conducted. Western blot 
provided an average value of COX-2 protein content in each group and showed that 
only the HF/HF had a significantly increased amount of COX-2 compared to the C/C 
group. Neither HF/C nor C/HF are statistically different than C/C. Nevertheless, protein 
amount was positively and significantly correlated to COX2 mRNA level (Figure 3.7). 
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Immunofluorescence presented both protein localization and quantification of COX-2. A 
representative image from each group was presented and showed the relative quantity 
of COX-2 on the tissue section. Almost no visualized COX-2 staining could be seen in 
C/C. The most abundant COX-2 positive signal is received from HF/HF, followed by 
HF/C and C/HF.  
 
Discussion 
 
The results demonstrate for the first time a double-hit effect of a high fat diet on COX-2 
gene expression. Exposure to a high fat diet throughout the lifespan leads to a more 
severe activation of COX-2 than a simple maternal or post-weaning introduction. 
Furthermore, as opposed to maternal or post-weaning diet, alone, life-long high fat 
feeding exerts a synergistic effect on COX-2, resulting in a significantly greater induction 
of COX-2 in liver tissue.  
 
A previous study that used a mouse model stated that early-life exposure to a high fat 
diet programmed susceptibility to NAFLD development in the offspring [84]. Fetal 
programming thus may create an environment that is less resistant to the progression of 
pathogenic events.  The likelihood of developing liver disease dramatically increased in 
offspring exposed to high fat diets during fetal growth. This hypothesis was validated by 
both physiological and pathological evidence, which showed that the most definitive 
progression towards NASH occurred in the HF/HF group, rather than C/HF or HF/C 
[84]. This study agreed with this previous observation by showing the evaluation of 
hepatic damage and lipid accumulation, as well as the increased gene expression of the 
pro-inflammatory marker COX-2, a central reflection of both chronic inflammatory status 
as well as liver injury. These measurements reinforced the knowledge that the severity 
of liver damage is exaggerated when the offspring are exposed to a high fat diet during 
early development. The synergistic effect of maternal and post-weaning high fat diets on 
COX-2 gene expression was statistically significant and may biologically account for 
greater detrimental outcomes in adulthood. 
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Only certain types of cells can express COX-2 upon being stimulated by inflammatory 
signals, and these are mostly non-parenchymal cells (NPC) such as Kupffer and 
endothelial cells [254, 255]. For example, it has been suggested that peroxidization of 
fatty acids was responsible for activated COX-2 expression in NPC, but not hepatocytes 
[254]. Our immunofluorescent images showed that COX-2 protein abundance varied 
according to the time of high fat exposure, in agreement with the mRNA level. COX-2 
positive staining was seen sporadically at certain sites in HF/C and C/HF. In contrast, 
HF/HF treatment produced more COX-2 signal. This once again strongly suggested the 
maternal fetal programming effect, meaning that exposure to a high fat diet during early 
development primes the liver tissue of male offspring with a more intense response to 
post-weaning high fat contact. However, it was difficult to differentiate the cell types in 
the liver of HF/HF pups which produced excessive amounts of COX-2. Still, this 
outcome could be attributed to a wider range of NPC activation, or to hepatocyte 
activation. Further investigation is needed to answer this particular question.  
 
Interestingly, the hepatic fatty acid profile was also modified by high fat dietary 
treatment. Neither the control nor high fat diets contain significant amounts of 
arachidonic acid, which could account for the animals experiencing such an increase. 
However, the proportion of arachidonic acid increased in the liver of all HF-treatment 
groups in comparison with the control. Arachidonic acid is mainly distributed throughout 
the lipid bilayer, and functions as a major substrate for cyclooxygenase enzymatic 
reactions. In the presence of adequate amounts of linoleic acid or fully functional 
Δ6desaturase, the conversion of linoleic acid to arachidonic acid is enabled [256]. In our 
study, Δ6desaturase mRNA abundance positively correlated with COX-2 gene 
expression across high fat treatment groups, which suggests a direct crosstalk between 
the enzymes. Previous dietary studies have suggested that hepatic Δ6desaturase can 
be induced by low level of dietary intake of essential fatty acids [257]. Control diet (AIN-
93) was used in this study because it provides complete nutrients that optimally meet 
animal requirements. Therefore, the induction of Δ6desaturase could be triggered by 
other cellular signaling molecules that participate in COX-2 reactions.  
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Conclusion 
 
Based on the results of the present study, it is not surprising to find a synergistic effect 
on hepatic physiology as a result of combined maternal and post-weaning high fat 
feeding. The most intriguing part resides on the gene programming of COX-2.  This is 
the first study to date to demonstrate that a “double hit” impact occurred on the gene 
expression level. In addition, it was revealed that in high fat dietary models the body 
adapted to environmental changes, meaning that it produced more arachidonic acid as 
a substrate for the support of COX-2 catalysis. Pre-mRNA expression correlated with an 
mRNA level of COX-2, which suggests a transcriptional regulation of hepatic COX-2 by 
high fat diets. As regards the current knowledge gap concerning the epigenetic 
regulation of COX-2, current study will further investigate DNA methylation and histone 
modifications in the next chapter.   
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CHAPTER 4. HIGH FAT DIET INDUCES EPIGENETIC ALTERATIONS OF COX-2 
GENE 
 
Abstract 
 
High fat diet is associated with pathological development and the progression of liver 
diseases. It is hypothesized that high fat diet changes the genomic landscape of DNA 
methylation and histone code, leading to differential expression of COX-2 in hepatic 
tissue. Methyl-DNA immunoprecipitation assay in combination with high-throughput 
sequencing (MeDIP-seq) and methylation-sensitive restriction enzyme sequencing 
(MRE-seq) were applied to illustrate the genomic landscape of DNA methylation 
modified by a high fat diet. The results showed that in all three high fat dietary groups, 
multiple regions of the COX-2 gene exhibited DNA hypomethylation, including the 
5’UTR and multiple coding regions. Chromatin Immunoprecipitation analysis (ChIP) 
showed that high fat diets programmed histone methylation and acetylation by 
increasing H4Ac, H3Ac and H3K4Me2, which characterize an open chromatin structure 
and active gene transcription. In conclusion, activation of COX-2 mRNA in the livers of 
high fat treated pups is associated with DNA hypomethylation and histone 
modifications. 
 
Introduction 
 
High fat dietary feeding results in various long-term health problems, and 
overproduction of COX-2 plays a central role. More particularly, COX-2 induction is 
known to actively participate in body weight and fat mass gains, blood pressure 
elevation, glucose and lipid level increases, glucose tolerance impairments and 
steatohepatitis development [258-260] COX-2 performs critical biological functions, so 
its expression should be closely monitored.  
 
Epigenetic modification dynamically orchestrates gene expression. It actively 
participates in the processes of cell differentiation, proliferation, and apoptosis [261] 
primarily through transcriptional and post-transcriptional manipulation of gene activity 
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[262]. The epigenetic profile is subject to re-modulation through inter- or intracellular 
signaling[263]. Therefore, the management of epigenetics is a novel contemporary 
therapeutic approach for the treatment of certain diseases.  
 
It has recently been recognized that dietary fat molecules have the potential to stimulate 
cellular epigenetic signals, profoundly affecting chromatin structure as well as gene 
expression, signaling pathways, and subsequent biological processes [264]. Consuming 
a high fat diet increases the risk of obesity and metabolic syndrome, which are often 
accompanied by low-grade chronic inflammation [265]. Moreover, high fat diets have 
been previously shown to program the epigenetic profile across numerous tissues [225, 
266]. Reprogramming the histone code [200], together with altered DNA methylation 
[225], have been documented for differentially expressed genes in the high fat model. 
Although gene deregulation can be attributed to aberrant DNA methylation and/or 
histone modifications, it has been considered to play a role in the production of 
pathophysiological outcomes [267]. However, it remains unclear whether, first, the 
alteration of DNA methylation and/or histone modifications are solely accountable for 
high fat-induced COX-2, and secondly, whether the timing of exposure to a high fat diet 
differentially shapes the epigenetic profile.  
 
A wide range of stimuli, including pathogens, cytokines, nitric oxide, and growth factors, 
are known to quickly but transiently activate COX-2 transcription [268]. Depending upon 
the cell type and stimulus, transcriptional control of COX-2 depends on a combination of 
transcription factors that bind to specific sites on the 5’-UTR (untranslated region) of the 
gene. More particularly, binding motifs of NF-κb (nuclear factor κb), AP-1 (activator 
protein 1), and CREs (cAMP-response elements), were found at gene 5’UTRs [269]. 
Transcription of COX-2 is also influenced by the acetylation status of histone and non-
histone proteins. Upregulation of p300, a histone acetyltransferase (HAT), activates 
COX-2 by acetylating NF-kB components [270]. By contrast, HDAC inhibitors suppress 
the activation of COX-2 expression in human primary myometrial cells [271] and cancer 
cell lines [272] by preventing the binding of transcription factor c-Jun to the COX-2 
promoter.  
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DNA methylation status may likewise affect COX-2 expression because two CpG 
islands are located at the core promoter of COX-2, the hypermethylation of which 
usually results in transcriptional silencing [273]. On the other hand, post-transcriptional 
regulation of COX-2 can occur through changes in its mRNA stability [274]; the 3’-UTR 
of COX-2 contains numerous AU-rich elements (AREs), which are bound by specific 
trans-acting ARE-binding factors. Many of these AREs are located within the first 150 
nucleotides of the COX-2 3’-UTR. CUGBP2 is a RNA binding protein. When it is bound 
to specific AREs within the first 60 nucleotides of the 3’-UTR, that stabilizes COX-2 
mRNA while inhibiting its translation. Consequently, there are many known checkpoints 
for the study of COX-2 gene expression. However, there is a lack of up-to-date 
understanding of the epigenetic-based molecular mechanisms by which high fat diet 
activates COX-2 gene expression. Our study aims to investigate the epigenetic 
regulation of COX-2 using a high fat diet, and seeks to determine whether the timing of 
high fat exposure generates a differential DNA methylation pattern and histone 
modifications. 
 
Materials and Methods 
 
Genomic DNA Isolation  
Ten milligram of liver tissue was ground in liquid nitrogen and genomic DNA was 
extracted in 600µL of Extraction Buffer (50mM Tris, pH 8.0, 1mM EDTA, pH 8.0, 0.5% 
SDS, 1mg/ml Proteinase K) at 55 ºC overnight. Lysates were centrifuged and 
supernatant was transferred to 2mL phase lock gel (PLG) (5’-Prime, Fisher Scientific 
Company, LLC).  Phenol/chloroform extraction (PCI) was performed to purify DNA. 
Briefly, equal amount of aqueous sample and organic extraction solvent were gently 
mixed in PLG tube and centrifuged at 16,000 g for 5 min to separate the phases. Upper 
phase was transferred and 1µL of RNase (Roche, 10mg/mL) was added with, followed 
by 1 hour of incubation at 37 ºC.  Another PCI and 1Xcholorofom extraction was 
performed. Purified DNA was precipitated with 1/10 volume of 3M Sodium Acetate (pH 
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5.2), and 2.5 volumes 100% EtOH.  DNA pellet was washed with 70% EtOH and 
resuspended in TE.   
 
Methyl-DNA Immunoprecipitation Assay (MeDIP) in Combination with High-
Throughput Sequencing (HTS) 
DNA methylation status in liver samples of rats was examined using sequencing-
coupled methylated DNA immunoprecipitation (MeDIP-seq).  Genomic DNA from each 
liver sample was purified and subjected to sonication to ~100–500 bp.  Sonicated DNA 
was end-repaired, A-tailed and ligated to adapters following the standard Illumina 
protocol.  Agarose size-selection was used to remove unligated adapters. A mouse 
monoclonal anti-methylcytidine antibody (Eurogentec) was then applied to adaptor-
ligated DNA for each immunoprecipitation.  Fifteen cycles of PCR were performed on 
the immunoprecipitated DNA using the single-end Illumina PCR primers. Final size 
selection (220–420 bp) was performed in a 2% agarose electrophoresis, and the 
resulting reactions were purified with Qiagen MinElute columns. Quality was checked by 
spectrophotometry and Agilent DNA Bioanalyzer, which indicated an average fragment 
size of 150 bp.  An aliquot of each library was diluted and used as template in four 
independent PCR reactions to confirm enrichment for methylated and de-enrichment for 
unmethylated sequences, compared to 5 ng of input (sonicated DNA). Each library was 
diluted to 8 nM for sequencing on an Illumina Genome Analyzer following the 
recommended manufacturer's protocol at the core facility of the Center for Comparative 
and Functional Genomics [275, 276].  
 
Chromatin Immunoprecipitation [275]  
ChIP analysis was employed according to a modified protocol [277]. Briefly, 200 mg 
frozen liver samples from each pup were ground and resuspened in phosphate buffered 
saline (PBS). Cross-linking was performed in 37% formaldehyde for 10 min on a rotator 
at room temperature. The pellet was resuspended in nuclei swelling buffer and lysed in 
SDS lysis buffer, both of which contained protease inhibitors. The chromatin was 
sonicated (Fisher Scientific, model 100 Sonic Dismembrator) on ice with 7 bursts for 40 
s and 2 min cooling interval between each burst with power set at 5. After removing cell 
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debris, sheared chromatin was diluted in ChIP dilution buffer. Diluted lysate (1 ml) was 
incubated with 2 μg of primary antibody of interest (Table 4.1) overnight at 4 C on a 
hematology mixer (Model 346, Fisher Scientific). Pre-blocked salmon sperm 
DNA/protein G agarose beads (60 μL, 33% slurry; Millipore) were then incubated with 
each chromatin sample for 2 hours, followed by centrifugation for 1 min at 4 C. 
Supernatant from incubation with normal rabbit IgG was saved as input. The pellets 
containing immunoprecipitated complexes were washed by a series of salt buffers, and 
antibody/protein/DNA complexes were eluted from Protein G agarose beads. After 
incubation at 65 C for 5 hours with 20 μL 5 M NaCl and 1 μg of RNase A to reverse the 
cross-linking, protein was removed by Proteinase K, and DNA fragments were 
separated from chromatin structure. DNA was purified by a Wizard SV Gel and PCR 
Clean up System (Promega). Purified DNA with a dilution series as a standard curve 
was quantified by real time PCR reaction with primers designed for COX-2 promoter 
(Table 3.4).  
 
Statistical Analysis 
ChIP results are expressed as mean±SEM. Mean differences in promoter protein 
binding, and histone modification between C/C and HF/HF groups were determined by 
SAS statistical analysis using one-way ANOVA. Significance level was set at P<0.05 for 
all comparisons.  
 
Results 
 
HF Diet Induced Hypomethylation of COX-2 Gene  
MeDIP-seq results showed a decreased DNA methylation intensity at the COX-2 5’UTR 
upstream and three coding regions (Figure 4.1, 4.2), whereas little difference was found 
at any β-actin regions (Figure 4.3, 4.4), suggesting that the exposure to high fat diet 
induced region-specific hypomethylation of COX-2 in rat liver. No DNA methylation 
differences were observed at the two CpG islands located at the proximal promoter 
region of COX-2. Decreased methylation intensity consistently occurred in all HF groups 
at 1KB, 2KB and 4KB of the coding region and 1.2 KB of 5’-flanking region.  
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Histone Modifications 
Chromatin Immunoprecipitation [275] analysis showed that histone acetylation (histone 
H3 and H4) and methylation at lysine residues (K4, 9 and 27) of histone H3 in HF/C and 
C/HF were not different from that of C/C group (data not shown). However, life-long high 
fat feeding (HF/HF) modulated histone tails of COX-2. A wide range of reduced 
association of HDAC3 to the DNA sequence was observed, which may correlate to the 
increased acetylated histone H3 (H3Ac) and H4 (H4Ac) at coding regions (Figure 4.5). 
Also, increased di-methylation of histone H3 lysine 4 (H3K4Me2) occurred across 
multiple sites at both upstream and coding regions. Increased tri-methylation of histone 
H3 lysine 9 (H3K9Me3) was detected at -1.2kb and +3kb. The overall biding levels of 
H4Ac, HDAC3 and H3K4Me2 are remarkably higher than IgG, whereas H3Ac, 
H3K9Me3 and H3K27Me3 are relatively low. Increased acetylation of histones H3 and 
H4 often suggests an open chromatin structure and thus greater accessibility of DNA 
transcription regulators [278]. Hence, life-long feeding of a high fat diet programs 
histone modifications of the COX-2 gene in the liver, which in turn matches the activated 
transcription patterns.  
 
Discussion 
 
This is the first report concerning how high fat diet-induced COX-2 gene expression is 
associated with persistent decreased DNA methylation at 5’ flanking and multiple coding 
regions. However, histone reprogramming, unlike DNA methylation, can be detected 
only in HF/HF pups, meaning that the modifications were dependent on the stage of life 
during which exposure to a high fat diet occurred. 
 
The interaction between nutritional and epigenetic influences on gene regulation has 
been of great interest to scientists who deal with chronic diseases and the improvement 
of human health. For decades, the limited experimental technology for the detection of 
DNA methylation constrained most studies to focus exclusively upon the impact of the 
diet on the methylation profile within a limited region of a single gene, and its 
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association with gene expression. The combination of MeDIP-seq and MRE-seq provide 
a detection method that provides a comprehensive high-resolution genome-wide 
coverage. This allows researchers to map out a slight shift in DNA methylation in the 
human genome [279].  
 
High fat diets have been shown to mediate DNA methylation on the gene promoter and 
affect gene expression, which thereby leads to physiological alterations. The genome is 
composed of gene and non-gene associated regions. This study investigated the effects 
of high fat diets on the DNA methylation pattern within the associated genetic region, 
including the promoter, coding, and downstream regions. A study reported that high fat 
diets induced greater DNA methylation in the leptin promoter, which parallels the 
decrease in the expression of leptin [229]. Using a genome-wide promoter to analyze 
DNA methylation has shown that fatty acids increase the methylation of PPARγ 
coactivator-1 (PGC-1α) in skeletal muscle cells [280]. A recent study, which used 
Illumina’s Infinium Bead Array, showed that a short period of high fat overfeeding 
induced genome-wide DNA methylation changes [281]. Still, there is no evidence on 
how maternal and post-weaning diet, alone or combined, can impact DNA methylation 
profile of COX-2 in the livers of the offspring. Combining two advanced sequencing 
methods, namely MeDIP-seq and MRE-seq, allowed us to be the first to present 
evidence that high fat diets induce region-specific hypomethylation of COX-2 in the liver 
of rats. 
 
DNA methylation that occurs at genomic locations other than the promoter region can 
affect gene expression as well. It have been previously showed that a high fat diet was 
able to induce COX-2 gene transcription, independent of the feeding period. The 
present study observed that high fat feeding resulted in DNA hypomethylation at the 5’ 
upstream and coding region of COX-2. Generally speaking, DNA hypomethylation is 
closely associated with gene repression or silencing. Our results thus suggest that high 
fat dietary intake delivers a strong signal to the epigenome, generating epigenetic 
behaviors, which in turn cause DNA hypomethylation in regions other than the 
promoter: this might be related to activation of COX-2. In addition, the existence of 
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positive correlations between DNA methylation in regions other than the promoter 
sequence and COX-2 gene enhancement might lead to the discovery of novel 
regulatory regions.  
 
High fat diets enabled alterations of DNA methylation profiles, which led to further 
investigation of histone modifications. This study investigated several histone variations 
of interest, and found that the histone patterns for HF/C and C/HF were quite different 
than HF/HF. Comparing to the C/C group, no sound evidence of altered histone 
modifications was found in HF/C or C/HF. It thus remains difficult to define any possible 
participation of these histone modifications by the activation of COX-2, or DNA 
hypomethylation at any genetic region in HF/C and C/HF groups. Nevertheless, there 
appears to be a direct link to the HF/HF group. In most cases, histone acetylation, 
namely H3Ac and H4Ac, and H3K4Me2, are associated with transcriptional activation. 
Unlike DNA methylation, a particular configuration of histones depicts a very unique 
pattern in response to exposure of a high fat during different stages of life. It is worth 
noting that the effects of double-hit theory were reflected on the gene expression level 
of COX-2, as well as some physiological measurements, but neither for DNA 
methylation nor for histone modifications. Although changes in histone modifications 
were only detected in HF/HF, we cannot rule out the possibility that other histone 
modifications were taking place in these treatment groups, given the limited 
modifications tested and current knowledge of the histone code.  
 
Fatty acids have been described as signal transducers that can be sensed by the 
epigenome [264]. Our results revealed a full landscape of DNA methylation profiles of 
COX-2, and showed that high fat diets removed methyl groups from CpG sites in 
multiple regions. The length of the traditional basic promoter of COX-2 is limited to 1kb, 
which comprises two detectable CpG islands. In our study, none of the changes, or only 
minimal changes, were identified by MeDIP-seq within this promoter region or the CpG 
islands, while a substantial reduction in methylation intensity was observed in the 
promoter upstream and coding regions, which correspond to the activation of COX-2. 
Interestingly, the location and grade of reduction is similar among all HF groups, 
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regardless of the stage of life during which exposure to a high fat diet occurs. Thus, 
DNA hypomethylation of the COX-2 gene is less likely to be connected to a double-hit 
effect on COX-2 mRNA abundance in this particular model.  
 
Conclusion 
 
Our findings provide insight into nutritional modulation of the epigenome, which is 
involved in liver health and function. For the first time anywhere, the impact of a high fat 
diet on the full landscape of DNA methylation of COX-2 was showed in the livers of rats. 
In our high fat feeding models, hepatic COX-2 activation is persistently accompanied by 
DNA hypomethylation, but is not accompanied by histone modifications. These region-
specific hypomethylations induced by high fat diet are positively associated with 
changes in gene expression. Future site-specific validation research should be 
conducted in order to confirm DNA methylation change and to identify the transcriptional 
functions of these regions.  
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CHAPTER 5. AN ENHANCER WAS CHARACTERIZED AT COX-2 UPSTREAM 
REGION 
 
Abstract 
 
High fat diets, regardless of the feeding period, significantly induced COX-2 gene 
expression in the livers of male offspring pups. Genome-wide methylated DNA 
immunoprecipitation (MeDIP) showed that multiple regions of COX-2 gene sequences 
were hypomethylated, which corresponds to the activation of gene expression. Bisulfite 
sequencing was therefore performed to confirm the MeDIP results, and showed that 
hypomethylation occurred on a specific CpG site within the 5’UTR of COX-2. This 
region was further cloned to test the transcriptional activity using a luciferase reporter 
assay. The results show that this hyomethylated region produced strong enhancer 
activity. Further characterization showed that the binding elements HOXD8, RAF and 
CTCF contribute to the enhancer’s activity at different levels. In addition, the 
transcriptional activity of this enhancer cannot be further induced by the presence of 
arachidonic acid. In conclusion, high fat induced hypomethylation of this enhancer may 
be responsible for triggering gene activation of COX-2.  
 
Introduction 
 
COX-2 is present in cells in minute amounts under normal conditions [282], which 
justifies why induction of the gene is necessary and under exquisite regulation. Many 
experiments have been conducted to study COX-2 gene regulation, such as the 
Luciferase reporter assay, a widely used lab tool that is used to determine promoter 
strength and enhancer activity. Various cis-elements in the human COX-2 promoter 
were revealed that operate to control luciferase reporter activity. These core promoter 
elements, including nuclear factor kappaB (NF-kB), CCAAT/enhancer-binding protein 
(C/EBP) and cyclic AMP-response element (CRE) sites, were shown to be modulated in 
response to environmental stimuli, such as sulforaphane [283] and 6-
(Methylsulfinyl)hexyl isothiocyanate [284]. These critical binding elements are 
exclusively located within 300 base pairs upstream of the transcription starting site 
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(TSS). Highly conservative binding domains for CREB, NF-Kb, AP-1, and C/EBP can 
also be found within the promoter region of murine COX-2 [285]. Despite the fact that a 
number of transcription factors are commonly found in humans, murine, and rats, each 
of them may exhibit unique responses toward different environmental stimuli, and these 
require further inspection and specification. Nevertheless, the investigation of the 
5’UTR’s regulatory role of COX-2 has never gone beyond its promoter, ranging from -
900 to TSS.  
 
In the previous chapter, an important aspect was presented that high fat diet actively 
manipulates COX-2 gene expression by modifying the landscape of its epigenome. 
Three hypomethylated regions in the high fat feeding models were identified, two of 
which situate in the gene body, and the other in the 5’UTR. The hypomethylation of 
DNA fragments in this particular dietary model perfectly correlates with the transcription 
level, and may or may not account for the gene activation of COX-2. Little research has 
been done on these particular regions to determine whether or not they exhibit any 
regulatory functions or transcriptional activities. In addition to the single CpG sites that 
are spread over the entire gene body and 5’UTR, two CpG islands are primarily 
distributed in the proximal promoter region. Methylation of CpG sites within the promoter 
can lead to gene silencing. However, these two CpG islands are barely methylated. 
Alteration of them is independent of high fat treatment as opposed to the single CpG 
sites, the methylation of which can be reduced by high fat diet. Even though the MeDIP-
seq provides an overview of the DNA methylation pattern of COX-2, it is quite difficult to 
pinpoint the CpG site(s) that were truly modified. In addition, we cannot rule out the 
possibility that the hypomethylated CpG sites varied in the three high fat groups. 
 
The traditionally defined rat COX-2 promoter does not cover this particular region 
ranging from -1.2kb to -1.1kb. This short DNA fragment contains multiple TF binding 
elements, several of which have not been studied in the context of COX-2 gene 
regulation. Moreover, in contrast to the default condition, which is highly methylated, the 
DNA methylation level in this region was nearly evened out by using high fat diet. In 
other words, the fold of reduction of methylation intensity in the 5’UTR region exceeds 
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those in the coding region. On the other hand, methylation of CpG regions downstream 
of the transcription starting site doesn’t block elongation, which means it may not 
critically be involved in transcription initiation [286]. Thus, this study is particularly 
interested in exploring this hypomethylated region in the vicinity of the COX-2 core 
promoter, because it may also represent an undefined regulatory region (enhancers, 
silencers, boundary elements/insulators) working in concert with the promoter. In order 
to answer the questions proposed above regarding methylation of which CpG sites were 
altered by high fat diet and the degree to which this region contributes to COX-2 gene 
transcription, bisulfite sequencing and a series of luciferase reporter assays were 
conducted.  
 
Materials and Methods 
 
Bisulfite Sequencing 
To confirmation DNA methylation at 5’ upstream region (region 1), bisulfite conversion 
of genomic DNA was performed using EZ Methylation-Gold kit (Zymo Research, 
Orange, CA) according to the manufacturer’s instructions. Converted DNA was 
amplified in 5X LongAmp Taq Buffer (XX), 10 μM dNTPs, 5 μM forward and reverse 
primers (-1533 to -1109), and 1 U of Long Amp Taq polymerase. The cycling conditions 
used were as follows: 45 cycles of 95°C for 30 seconds, followed by 95°C for 10 
seconds, 48°C 30 seconds and 65°C for 30 seconds, then 65°C for 10 minutes. PCR 
products were elongated with 5X Go Taq Flexi Buffer, 25 mM MgCl, 10 mM dATP, and 
Go Taq Flexi DNA polymerase at 72°C for 10 minutes. The PCR product was 
concentrated with a DNA Clean & Concentrator -5 kit (Zymo Research), ligated 
overnight at 16°C into the TOPO PCR 4.0 TA (Invitrogen) in accordance with the 
manufacturer's instructions and transformed into DH5α E.coli (New England Biolabs). 
Plasmid DNA was isolated with the QiaPrep Spin Miniprep kit (Qiagen XX) and at least 
50 independent recombinant clones per sample sequenced at the University of Illinois 
Core Sequencing Facility (Urbana-Champaign, IL) and the methylation data was 
compiled using the BISMA (Bisulfite Sequencing DNA Methylation Analysis) software 
(http://biochem.jacobs-university.de/BDPC/BISMA/). The lower threshold conversion 
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rate was set to 90%, while all the other analysis parameters were set to the BISMA 
default values (Mamrut, Harony et al. 2013). 
 
Cell Culture and Arachidonic Acid Treatment 
The human prostate cancer cell lines (PC3) was obtained from the American Type 
Culture Collection (Manassas, VA) and was cultured in Roswell Park Memorial Institute 
(RPMI) medium supplemented with 5% (v/v) fetal bovine serum (Mediatech; Herndon, 
VA) and 100 IU/mL Penicillin, and 100 μg/mL Streptomycin (Mediatech; Herndon, VA). 
Cells were maintained at 37 °C in 95% humidity and 5% CO2. For Arachidonic acid (AA) 
treatment, cells were first seeded at a density of 0.5×10^6 cells in a 6-well plate, grown 
for 16 h, and then starved with 0.3% FBS supplemented with 1.25mg/mL fatty acid free 
BSA (Sigma) for 48 hours before treatments. AA was neutralized with 1N NaOH and 
dissolved in the starvation media. Cells were incubated with 10μg/ μL AA for 30min, 1h, 
2h and 3h to induce COX-2 expression.  
 
Plasmid Construction and Methylation 
Wild type COX-2 upstream fragments -1234/-1199, -1204/-1160, -1164/-1131, -1234/ 
+30, -1234/ -1029, -1234/ -917 and -1234/ -814 were amplified by a Thermal Cycler 
(Applied Biosystems) using LongAmp Taq DNA polymerase (New England Biolabs). 
The primers/fragments can be found in Table 3. 1. The reaction was performed at 94°C 
for 30 sec, followed by 40 cycles of 94°C for 30 s, 67°C for 60 sec and 65°C for 50 sec 
to reach maximum amplification, and ended with 10 min of 65°C for final extension. The 
restriction enzymes used below are all acquired from New England Biolabs. The 
fragment of -1234 to -+30 was cut with NheI, gel-purified, and cloned into the NheI site 
of a luciferase reporter vector PGL3-basic (PGL3-b) (Promega Corporation). This 
generated forward and reverse- orientated products. The forward product was cut with 
SacI, deriving a partially truncated promoter region (-774/+30) and upstream region (-
1234/-774), and SmaI generating a fragment of -1234/-1131. The upstream fragment (-
1234/-774) was cloned into the SacI site of a PGL3-promoter (PGL3-p) vector and 
generated forward and reverse- orientated products. This forward product was further 
cut with SmaI and generated two upstream regions (-1234/-1131 and -1131/-774) in 
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PGL3-p vector. The reverse product of PGL3-b (+30/-1234) was cut with SmaI and 
derived a partially truncated region (-1131/-1234), which was cloned into PGL3-p vector. 
The fragments of -1234/ -1029, -1234/ -917 and -1234/ -814 were cut with SacI, gel-
purified, and cloned into the SacI site of PGL3-p, from where a forward- orientated 
product was generated for each fragment. Selected plasmids were methylated using 
CpG Methyltransferase(M.SssI) (New England Biolabs). 
 
Transfection and Luciferase Reporter Assay 
PC3 cells were plated in 24-well plate for 24hr prior to transfection.  Each plasmid (0.5 
ug) were transfected into each well using Superfect transfection reagent (Qiagen; 
Valencia, CA) following manufacturer's instructions.  Meanwhile, an empty reporter-
gene plasmid was transfected following the same procedure, and used as a control. 
Cells were maintained in transfection for duration of 3 hr.  Cells were then lysed with 
Passive Lysis Buffer (PLB) and subjected to one round of freeze-thaw. Luciferase 
activity was measured using Single-Luciferase Assay (Promega) with a luminometer 
(Fermomaster FB12, Zylux Corporation; Huntsville, AL).  For each experimental 
condition, six replicates were performed.  
 
Prediction of Transcription Factor Binding Sites and Site-directed Mutagenesis of 
CTCF, RAF and HOXD8 Binding Element 
Transcription Element Search System (TESS) was used to predict transcription factor 
binding sites in DNA sequences. It identifies binding sites using site or consensus 
strings and positional weight matrices from the TRANSFAC, IMD, and CBIL-GibbsMat 
database. Mutant -1234/ -1131 construct were prepared using QuickChange Lighting 
Multi Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). Primers 
contained mutations in putative CTCF, RAF and HOXD8 binding site (Table 3.1). PCR 
products were digested with DpnI restriction enzyme (Agilent Technologies) to remove 
the template DNA. These DNA constructs were sequenced to confirm the mutation site.  
 
Statistical Analysis 
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Percent methylation patterns of all CpG sites were extracted and for each site the 
probability of the observed pattern was calculated assuming a model of stochastic 
binomial distribution for the calculation of the p-value. A parallel comparison using one-
way ANOVA was performed in between different transfections.  
 
Results 
 
Bisulfite Sequencing Showed a Site-specific CpG Hypomethylation 
After MeDIP analysis, the region upstream of the hypomethylated promoter was located. 
The specific upstream region from -1533 to -1109 was fully analyzed through bisulfite 
sequencing, and the results for the methylation pattern for all 9 CpG sites are presented 
on Figure 5.1. The graphical display of the average methylation at each CpG site 
reveals a differential distribution of methylated cytosines between the control group (C/C) 
and the high fat groups (HF/HF, HF/C, C/HF); The analysis of the average methylation 
percentage (Figure 5.2)(Table 5.1) for each clone indicates greater site-specific CpG 
methylation for the healthy control (C/C), compared to the high fat control group 
(HF/HF), specifically on the 8th CpG site (-1169). Hence, the 8th CpG site is persistently 
hypomethylated by high fat diet in this region.  
 
Identification of An Enhancer Element Located at the 5’ UTR  
To investigate the transcription function of the HF- induced hypomethylated fragment at 
the 5’ region upstream of COX-2, several constructs were prepared from the rat gene 
that contain this fragment (-1234/-1131, the hypomethylated region from MeDIP result) 
as well as downstream genomic sequences through +30 and -774. These sequences 
were cloned into the PGL3-B luciferase reporter vector and their ability to drive 
regulated transcription was measured (Figure 5.3). The basic promoter of COX-2 (-
774/+30) has greater transcription activity, but not as great as the full fragment does (-
1234/+30). Therefore, the fragment of -1234/ -774 was cloned into Pgl3-p luciferase 
reporter for further investigation. This construct containing the portion of the 3’ upstream 
(-1234/-774) region exhibited a relatively small but reproducible increase in transcription. 
Deletion in the 3’ direction yielded a construct (-1131/-774) that lost transcription activity 
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and another construct (-1234/-1131) that had significantly increased transcription 
activity. The fragment containing the -1234/-1131 region, regardless of the orientation, 
produced the highest transcription activity. When this DNA sequence was placed in 
front of the Pgl3-b vector, it resulted in an even higher transcription induction than the 
traditional promoter of COX-2 (Figure 5.3). Therefore, the DNA fragment of -1234/-1131 
exhibits transcriptional enhancer activity, and it appears that this fragment can serve as 
an alternative promoter to COX-2.  
 
Effects of in vitro CpG Methylation on Enhancer Activity 
In vitro methylation at CG dinucleotides in a transfecting plasmid can inhibit gene 
expression in mammalian cells. In order to test if the methylated enhancer lost its 
transcriptional activity, PGL3-P and PGL3-P containing the COX-2 enhancer were 
methylated (Figure 5.5). The results showed that methylation of both plasmids have 
deprived their original transcriptional activities. PGL3-P containing the COX-2 enhancer 
exhibited 3 times greater ability to drive regulated transcription than PGL3-P. After 
methylation, the transcriptional activity driven by the COX-2 enhancer was only 
increased by less than 1 time. Therefore, in vitro methylation of the plasmid resulted in a 
significant reduction of the transcriptional activity driven by COX-2 enhancer. This result 
also suggested that the transcriptional activity of this COX-2 enhancer was not fully 
dependent on methylation status. Other factors, such as the binding of TFs that are not 
affected by DNA methylation, may sustain the remaining activity of the enhancer.  
 
Transcriptional Activity of Different Fragment of COX-2 Enhancer  
In order to locate the possible critical binding elements within this enhancer, three 
shorter DNA fragments (Fragment 1, -1234/-1199; Fragment 2, -1204/-1160; Fragment 
3, -1163/-1131) (Figure 5.6) were cloned into PGL3-P in both forward and reverse 
position and were checked for their transcription activity (Figure 5.7). All of them 
produced significantly higher luciferase signal than PGL3-P. In comparison to the 
control plasmid, fragment 1 exhibited 3 times higher activity while fragment 2 and 3 
exhibited 7 to 8 times higher activities in forward position. Even though the activity was 
lower when these fragments were placed in reverse orientation, they were still able to 
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generate 3 to 4 times higher activity than the control plasmid did. These results 
suggested that each fragment was sufficient to produce transcriptional enhancer activity, 
and that fragment 2 and 3 might comprise stronger TFs binding elements to drive the 
transcription initiation.    
 
Site-directed Mutagenesis Revealed Crucial Transcription Factors 
In order to characterize the critical and novel binding factors to this enhancer, binding 
sites for predicted transcription factors were mutated and tested them with a luciferase 
reporter assay. The predicted TFs have been mapped out in Figure 5.6 based on the 
TESS analysis. The binding of these TFs tend be clustered. Therefore, mutation of the 
DNA sequences that bind to one TF may also affect the binding of the ones in the 
nearby vicinity. Several TFs have been shown to be associated with COX-2 
transcriptional activity in a variety of cell types, including NF-1 [287], Ets-1 [288], c-Myb 
[289], YY1 [290], PU.1 [291], HSP1 [292] and AP-2 [293]. Mutation of the binding 
elements for these TFs is prone to alter transcriptional activity. In contrast, there have 
not been any studies showing that COX-2 gene transcription is subject to the regulation 
of POU1F1α, NF-1/L, TEF, HOXD8, HSTF, GAL4, GCN4, RAF, CTCF and MAZ. Given 
the fact that POU1F1α, NF1-L, TEF, HSTF and GAL4 share consensus binding 
sequences with TFs that were known to regulate COX-2 transcription, we decide to 
begin the tests with RC2/HOXD8, RAF and CTCF. CTCF is of greater interest in the test 
due to its insulator properties [294, 295] and its close relevance to DNA methylation 
status [296]. The individual site-directed mutations were performed for each of them, 
generating three sets of enhancers that carried one mutation site at a time (Figure 5.8 
and 5.9). The Luciferase assay showed that mutated CTCF and RAF sites lessen the 
transcriptional activity of the original enhancer by 25%, whereas mutated HOXD8 sites 
entirely deplete transcriptional activity (Figure 5.9). These results, taken together, 
suggested that RC2/HOXD8, RAF and CTCF are potential contributors to enhancer 
activity.  
 
Enhancer Activity Cannot be Further Induced by Arachidonic Acid  
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In accordance to the previous publication, AA was used to induce COX-2 expression in 
PC3 cells.  Samples were harvested at different time points.  Compared to BSA control 
cells, the greatest induction of COX-2 mRNA was acquired at a time of 3 hours (Figure 
5.10). However, using the same treatment condition, luciferase activity of the enhancer 
element in both orientations cannot be further induced by AA treatment (Figure 5.11).  
 
Discussion 
 
To our knowledge, these results are the first to identify a novel enhancer element at 
5’UTR that is independent of the promoter sequence of the COX-2 gene. In high fat 
treatments, this enhancer element was persistently hypomethylated, which may 
contribute to the gene activation of COX-2 in the liver. Bisulfite analysis confirmed the 
MeDIP-seq map and pinpointed the possible hypomethylated CpG sites on this 
enhancer fragment.  
 
The MeDIP-seq results in Chapter 4 led to the identification of a novel enhancer at the 5’ 
UTR of COX-2. Rat model-based COX-2 gene analysis has not been as extensive as 
human and mouse analysis. This study preceded the previous research of rat COX-2 
gene regulation. It was able to target a specific region based on the fully revealed DNA 
methylation landscape of COX-2. In both humans and mice, a luciferase assay 
established the predominant regulatory role of the COX-2 core promoter. Promoter 
activities in these two species are quite significant. Mutations of these given TF binding 
elements can result in a dramatically reduced transcriptional activity toward LPS 
challenge [285, 297]. However, there appears to be a different regulation scenario for 
rat hepatic COX-2, if one consider that the promoter location of this gene is 
conservative across species. These results showed that the promoter activity of COX-2 
in rats was not as great as what had been seen in both humans and mice. Instead, 
when the tested fragment was extended and harbored the hypomethylated region at the 
5’ upstream region of the promoter, this yielded stronger activity. This is an essential 
piece of evidence that demonstrated that COX-2 activation in rat livers may require the 
DNA sequence at the region which is 5’ upstream of the promoter. A further set of 
experiments proved this point of view by revealing the enhancer activity of this particular 
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DNA fragment. Thus, it is speculate that consuming a high fat diet induces COX-2 at 
least partially by motivating the enhancer activity, and the hypomethylation that 
occurred on this enhancer could be an underlying mechanism which bridges the high fat 
signal and enhancer stimulation. This enhancer also presents activity which resembles 
that of the promoter. Additional investigations will be required to further characterize its 
properties.  
 
This study also provided the first evidence in rats that high fat diet undermethylated 
single CpG sites within this transcriptional enhancer. DNA methylation on both CpG 
islands and single/multiple CpG sites can be closely associated with gene expression 
and disease development. Many genes contain more than one CpG island on their 
genomes, and these are specifically associated with the start of the gene when they are 
within promoter regions. Likewise, methylation of CpG sites within the promoters of 
genes can lead to gene silencing, whereas reduced methylation intensity of CpG sites 
has been associated with gene activation. This “on and off” phenomenon has been 
found frequently in cancer [298, 299] and has also been observed in numerous other 
types of diseases, such as heart disease [300], chronic kidney disease [301] and 
NAFLD [302]. Activation of the human COX-2 gene was previously found to be inversely 
correlated with the DNA methylation of a single CpG site within the promoter of patients 
with chronic periodontitis [303]. In contrast to this study, rat COX-2 was induced when 
methylation of a single CpG site within the enhancer was decreased, which means it is 
with fewer relevancies to promoter methylation. This observation supports the 
increasing amount of emerging evidence regarding mice [304] and human studies [305, 
306] that DNA methylation state could be closely associated with gene expression 
alteration. Furthermore, these cell type- [307] and lineage-specific [308] DNA 
methylations of a given enhancer were expected to produce gradients of expression in a 
wide range of tissues. Thus, DNA hypomethylation of this enhancer of hepatic COX-2 
might be a very particular and unique consequence of a high fat diet.  
 
Nevertheless, it was wondered how DNA hypomethylation of this enhancer might be 
associated with COX-2 induction. Distal methylation sites that were associated with 
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expression were in a particular class of enhancers [306]. These enhancers were bound 
to transcription factors depending on the DNA methylation state [306]. In other words, 
altered DNA methylation at a given CpG site in these enhancers may affect the 
downstream gene transcription by changing the interaction between DNA structure and 
transcription factors. TESS analysis revealed a number of TFs that can potentially bind 
to this enhancer sequence. Among them, CTCF generally binds to the hypomethylated 
region [296], which partially protects surrounding genetic sequences from methylation 
[309]. It can form boundaries by binding to the regions that are between enhancers and 
promoters, and thereby block enhancer function [294, 295]. CTCF shares consensus 
sequences with many other TFs, such as Sp1 and AP-2. Therefore, even though 
mutation of CTCF binding sequence reduced transcriptional enhancer activity, it is not 
assured that CTCF truly interacted with the enhancer. Additional sets of experiments 
and analysis may allow revealing this point. The DNA sequence containing the 8th CpG 
that is hypomethylated in high fat groups constitutes a binding spot for RAF. Mutation of 
this binding site undermined the transcriptional activity of COX-2 enhancer, although it 
is not clear as to whether DNA methylation of this CpG site affected RAF binding. There 
hasn’t been a solid conclusion concerning the regulatory function of HOXD8 during 
COX-2 activation. Our research is the first to reveal that removal of HOXD8 in COX-2 
enhancer not only reduced the enhancer activity, but also diminished SV40 promoter 
activity carried by PGL3-P. However, there hasn’t been a reasonable explanation 
provided for this phenomenon. Although these DNA sequences appear to contain 
elements that are essential to enhancer activity, further characterizations are 
indispensable for fully defining this methylation-sensitive enhancer of COX-2. 
In addition to characterizing the transcriptional function of hypomethylation region, the 
current study is interested in finding a possible physiological cause that can explain why 
and how it happened in the first place. In chapter 3, increased arachidonic acid content 
of the livers of high fat treated pups was showed. Given that it was the sole substrate of 
COX-2 enzymatic reaction, we want to determine whether arachidonic acid can promote 
enhancer activity in order to induce COX-2 gene expression. However, the supply of 
arachidonic acid did not further elevate enhancer activity in the PGL3-P construct. 
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There are multiple explanations why this might happen. First, arachidonic acid does not 
affect this enhancer. Second, the induction condition for human PC3 cells cannot be 
applied to rat COX-2. Third, arachidonic acid might induce enhancer activity by reducing 
the methylation intensity, which cannot be fulfilled in this plasmid because the inserted 
DNA sequence is demethylated. Given these concerns, an alternative experimental 
design, such as using a rat cell line, might offer better insights that can reveal the 
physiological causes.  
Conclusion 
 
In summary, the current study showed that a single CpG site at 5’UTR was persistently 
hypomethylated by high fat diets. This study also identified the enhancer property of this 
hypomethylated region by comparing its transcriptional activity to other DNA sequences. 
It is speculated that altered DNA methylation is associated with enabled enhancer 
activity, which triggers COX-2 transcription. Additional characterization and exploration 
of physiological motivators of this enhancer will be conducted in future research. 
 
Undermethylated genomic regions, specifically promoters or enhancers, have been 
associated with the elevated expression of downstream genes. However, previous work 
may have overlooked the roles that enhancer DNA methylation, and single CpG site 
demethylation, has played in regulating gene expression. These regions may be 
actively involved in other scenarios that provoke COX-2 transcription, so correcting 
misconstructed epigenomes on these enhancers/ regions may efficiently reduce 
transcription and subsequent physiological responses. COX-2 inhibitors have long been 
used in the anti-inflammatory drug category, but produce a significant increase in heart 
attacks and strokes [310]. Studies using epigenetic tools may offer a different 
perspective in inhibiting overproduction of COX-2 in such diseases by correcting 
transcription levels using epigenetic therapeutic strategies.  
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CHAPTER 6. TABLES AND FIGURES  
  
 
 
Figure 3.1 Growth curve (A) and weekly caloric intake (B) of control (C/C) offspring and 
offspring fed a high fat diet during gestation and lactation (HF/C), postweaning (C/HF) or 
throughout life (HF/HF).  Values are mean ± SEM, n=10 animals.  Some error bars are 
too small to be seen.  
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Table 3.1 Body weight (BW) and caloric intake analyzed by Repeated ANOVA1, 2  
BW HF/C C/HF 
C/C 0.5 0.05 
HF/HF 0.009* 0.11 
 
Kcal HF/C C/HF 
C/C 0.79 <0.0001* 
HF/HF <0.0001* 0.64 
1 Comparison are made between each two treatment groups 
2 *P<0.05  
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Figure 3.2. Representative images of H&E staining (upper panel) and ORO staining (lower panel) in livers of C/C, 
HF/C, C/HF and HF/HF offspring. Objective, 20X, Scale bar, 200µm. 
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Figure 3.3. Scattered plot of hepatocellular vacuolation counting (upper panel) and ORO 
evaluation (lower panel). Each symbol represents one individual sample.  Horizontal lines 
represent mean value. n=8 individual animals. Individual treatment with different letters differ 
(P<0.05) 
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Figure 3.4. Hepatic (top) and plasma (bottom) TAG levels were measured in four 
treatment groups. Data are presented as means ± SEM, n= 6. Letters are assigned by 
LSD. Individual bars with different letter differ (p<0.05). 
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Figure 3.5 Expression of COX-2 mRNA, pre- mRNA and Δ6Desaturase mRNA were 
measured by qPCR and normalized to internal control gene β-actin. Data are presented 
as means ± SEM, n= 8. Letters are assigned by LSD. Individual bar with different letter 
differ (p<0.05). 
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Table 3.2. Gas Chromatograph analysis of fatty acid composition in liver1,2 
  Diet 
Fatty Acid Composition CC (%) HFC (%) CHF (%) HFHF (%) 
(Lauric acid)12:0 44.6±0.03 46.8±0.03 49.8±0.03 57.0±0.03 
(palmitic acid)16:0 14.5±0.006 15.3±0.01 9.6±0.01 5.9±0.01 
(palmitoleic acid, n-7)16:1 6.7±0.004
a 
3.2±0.005
a,b 
0.3±0.001
b 
0.2±0.001
b
 
(stearic acid)18:0 4.7±0.004 4.7±0.003 3.9±0.2 3.5±0.01* 
(oleic acid, n-9)18:1 16.7±0.02 13.4±0.02 15.8±0.008 15.1±0.01 
(linoleic acid, n-6)18:2 8.7±0.004
b 
10.0±0.004
a,b 
12.2±0.007
a 
11.1±0.01
b 
(Arachidonic acid, n-6 )20:4 4.3±0.005
b
 6.4±0.003
a
 8.3±0.005
a
 7.3±0.1
a
 
1
Values are means ± SEM, n=6. 
2
Letters were assigned to indicate significant different between treatment groups. 
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Table 3.3. Two-Way Factorial Interaction1  
 
Maternal Postweaning Maternal * Postweaning 
COX-2 mRNA <0.0001 <0.0001 0.06 
COX-2 Protein 0.004 0.12 0.01 
Δ6Desaturase 0.0008 0.0014 0.09 
TAG 0.22 <0.0001 0.03 
Vacuolation 0.39 0.0012 0.1 
ORO 0.55 <0.0001 0.1 
(Lauric acid)12:0 0.19 0.07 0.6 
(palmitic acid)16:0 0.26 0.0003 0.17 
(palmitoleic acid, n-7)16:1 0.22 0.01 0.34 
(stearic acid)18:0 0.93 0.25 0.54 
(oleic acid, n-9)18:1 0.4 0.81 0.59 
(linoleic acid, n-6)18:2 0.53 0.13 0.02 
(Arachidonic acid, n-6 )20:4  0.26 0.003 0.04 
1
Interaction of main effects (maternal X postweaning) 
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Figure 3.6 Expression of COX-2 protein content in the liver of male offspring by Western 
blot (n=6). The bands presented the average level of OCX-2 protein in control and all high 
fat groups. Data are presents as means ±SEM, n=6. Letters are assigned by LSD. 
Individual bar with different letter differ (p<0.05). Actin was used as loading control to 
indicate total protein quantity.  
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Figure 3.7 Correlation of Δ6Desaturase mRNA (top), COX-2 pre-mRNA (middle) and 
protein (bottom). Each symbol represents one individual sample. Regression line was 
calculated after the analysis.  
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Figure 3.8. Representative images of COX-2 protein content in livers of C/C, HF/C, 
C/HF and HF/HF offspring. Protein content ofCOX-2 in liver was analyzed by 
immunofluorescent staining using an antibody against COX-2 protein and an Alexa 
Fluor 647-labeled secondary antibody (red, middle panel). Nuclei were counterstained 
with Hoechst 33342 fluorescent stain (blue, top panel). The two pictures were merged to 
show the cytoplasmic location and distribution of COX-2. Objective, 63x. Scale bar, 20 
μm. 
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Table 3.4. Primer sequences used in real-time PCR analysis of genes  
Gene Name (Ensembl ID #) Sequences 
rActb mRNA (ENSRNOE00000310180) Forward (+451), 5’- GAG ACC TTC AAC ACC CCA GC-3’ 
Reverse (+526), 5’- CAG TGG TAC GAC CAG AGG CA -3’ 
rΔ6D mRNA (ENSRNOE00000222342) Forward (+165), 5’- TGA CAG GCT CAG GAA ATG TC-3’  
Reverse (+257), 5’- TTG CGA TCA ATC ACC AGC-3’ 
rCOX-2 mRNA (ENSRNOT00000003567) Forward (+1048), 5’- ATTACTGCTGAAGCCCACC -3’  
Reverse (+1115), 5’- TGTTCCAGACTCCCTTGAAG -3’ 
rCOX-2 pre-mRNA 
 
Forward (+2972), 5’- CAGGCATCGGACTCTGCTAT -3’  
Reverse (+3052), 5’- AGCAGCACAATCAGGGGA -3’ 
rCOX-2 ChIP 
 
Forward (-1664), 5’- CAGTCTGTGCACTCAGTTGAGATGG -3’  
Reverse (-1598), 5’- TTCCGTGTATGGCACTCCCAA -3 
rCOX-2 ChIP 
 
Forward (-1320), 5’- TTGCCCAGACTGCTTCAAAC -3’  
Reverse (-1217), 5’- CGTTCTTGGCATGAATGGAG -3’ 
rCOX-2 ChIP 
 
Forward (-135), 5’- AACTGAGCGGAGAGCTTCAGGAG -3’  
Reverse (+68), 5’- TGGCAGGACACAGAGCTGAGTTC -3 
rCOX-2 ChIP 
 
Forward (+1048), 5’- ATTACTGCTGAAGCCCACC -3’  
Reverse (+1115), 5’- TGTTCCAGACTCCCTTGAAG -3 
rCOX-2 ChIP 
 
Forward (+1847), 5’- TCTCCAACCTCTCCTACTACAC -3’  
Reverse (+1934), 5’- TGTACTCACCTTTCACACCC -3 
rCOX-2 ChIP 
 
Forward (+2972), 5’- CAGGCATCGGACTCTGCTAT -3’  
Reverse (+3052), 5’- AGCAGCACAATCAGGGGA -3 
rCOX-2 ChIP 
 
Forward (+3967), 5’- CTCAAACAGGAGCATCCTG -3’  
Reverse (+4031), 5’- ATCAGTATGAGCCTGCTGG -3 
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Figure 4.1 MeDIP-seq results of COX-2. Displayed tracks include DNA methylation (MeDIP-seq) for rat COX-2 in liver tissue 
from C/C, HF/C, C/HF and HF/HF offspring. The dashed box highlights the hypomethylated region at COX-2 5’ upstream in all 
HF treated groups. Blue line illustrates COX-2 gene structure, with each square box represents an exon. Two CpG islands are 
marked at the bottom at their relative location.   
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Figure 4.2 Landscape of DNA methylation patterns (A) and gene structure (B) of COX-2. A. 
Y axils represents the MeDIP reads, X axils represents the relative location to TSS. 
Individual comparison was made between each high fat group (HF/C, top; C/HF, middle, 
HF/HF, bottom) and control. Hypomethylated region in 5’UTR was highlighted in the 
dashboxed as it may closely associated with gene transcription of COX-2. B. Ten exons 
were labeled according to the relative location. Two CpG islands were marked with arrows 
in gene structure illustration. Each hypomethlated region was tagged with hyphen.  
A. 
B. 
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Figure 4.3. MeDIP-seq results of β-actin. Displayed tracks include DNA methylation (MeDIP-seq) for rat β-actin in liver 
tissue from C/C, HF/C, C/HF and HF/HF offspring. Blue line illustrates β-actin gene structure, with each square box 
represents an exon. Two CpG islands are marked at the bottom at their relative location.   
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Figure 4.4 Landscape of DNA methylation patterns (A) and gene structure (B) of β-
actin. A. Y axils represents the MeDIP reads, X axils represents the relative location to 
TSS. Individual comparison was made between each high fat group (HF/C, top; C/HF, 
middle, HF/HF, bottom) and control. B. Six exons were labeled according to the relative 
location. One CpG island was marked with arrows in gene structure illustration. 
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Figure 4.5. Mapping of the histone structure of COX-2 gene in the liver of C/C (n=8) 
and HF/HF (n=8) groups. Acetylation of histone H4 (top), H3 (middle) and binding of 
HDAC3 (bottom) at upstream, promoter and coding regions of COX-2 were detected. 
Data are represented as the ratio to the value obtained with input DNA. The normal 
rabbit IgG was used as negative control to mark the non-specific association 
background for each tested region. Values are means ± SEM. *P<0.05 
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Figure 4.6 Mapping of the histone structure of COX-2 gene in the liver of C/C (n=8) and 
HF/HF (n=8) groups. Di-methylation of histone H3 Lysine 4 (top), tri-methylation of H3 Lysine 
9 (middle) and Lysine 27 (bottom) at upstream, promoter and coding regions of COX-2 were 
detected. Data are represented as the ratio to the value obtained with input DNA. The normal 
rabbit IgG was used as negative control to mark the non-specific association background for 
each tested region. Values are means ± SEM. *P<0.05 
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Table 4.1 Antibody Information 
Antibody Name 
Catalog Number Source 
Name Modification 
COX-2 H-300 Sc-32879 Santa Cruz 
H3Ac Ac-K9,14 06-599 Millipore 
H4Ac Ac-K5,8,12,16 06-866 Millipore 
HDAC3 H-99 sc-11417 Santa Cruz 
H3K4Me2 M-K4 07-030 Millipore 
H3K9Me3 M-K9 07-442 Millipore 
H3K27Me3 M-K27 07-449 Millipore 
IgG N/A sc-2027 Santa Cruz 
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Figure 5.1 CpG methylation within -1533 to -1109 upstream region of COX-2 coding 
region in liver of offspring from high fat fed groups. Distribution of methylation levels of 
individual CG sites within the analyzed region. *Indicates significant difference compared 
to the C/C group (P≤0.05). 
 
 
* 
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Figure 5.2 Methylation statuses of the nine CpG sites. Each column corresponds to 
one CpG site in the studied region, and each row represents average methylation of 
50 individual clones. 
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Table 5.1 Percentage of Methylation at each CpG site 
CpG site# 1 2 3 4 5 6 7 8 9 
CpG position -1481 -1457 -1441 -1431 -1410 -1217 -1213 -1169 -1134 
M
e
th
y
la
ti
o
n
 (
%
) 
C/C 97 85.3 91.2 93.8 76.5 84.8 76.5 64.5 87.9 
HF/C 96.4 82.8 89.3 92.9 58.6 72.4 86.2 53.6* 82.1 
C/HF 96.3 96.3 92.6 88.9 81.5 77.8 77.8 44.4* 88.9 
HF/HF 89.6 91.5 93.8 89.6 70.2 69.6 75 45.7* 78.3 
*p<0.05 comparing to C/C 
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Figure 5.3 Identification of the essential elements in rat COX-2 by luciferase assay. The 
diagrams on the top show the firefly luciferase reporter constructs driven by various rat 
COX-2 fragments of  -774/ +30, -1234/+30 and -1234/-1131 in Pgl3-basic. The luciferase 
activities from firefly were assayed and the relative luciferase activity was obtained by 
normalizing the firefly luciferase activity of constructed plasmids against the control 
plasmid luciferase activity. The results are expressed as mean ± the SEM of six 
replicated experiments. 
 
 
  79 
  
Figure 5.4 Identification of the essential elements in rat COX-2 by luciferase assay. The 
diagrams on the top show the firefly luciferase reporter constructs driven by various rat 
COX-2 fragments of -1234/ -774, -774/-1234, -1131/-774, -774/-1131, -1234/-1131 and -
1131/-1234  in Pgl3-promoter. The luciferase activities from firefly were assayed and the 
relative luciferase activity was obtained by normalizing the firefly luciferase activity of 
constructed plasmids against the control plasmid luciferase activity. The results are 
expressed as mean ± the SEM of six replicated experiments. 
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Figure 5.5. Luciferase activity of methylated constructs. Values of control are normalized 
to PGL3-p, values of +Me are normalized to PGL3-p+Me. The results are expressed as 
mean ± the SEM of six replicated experiments.  
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Figure 5.6. Transcription Element Search System (TESS) analysis of COX-2 enhancer. 
Three segments representing the left, middle and right part of this enhancer was 
constructed. The starting and ending nucleotide position was noted. The potential binding 
transcription factors are labeled at its predicted site.  
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Figure 5.7 Characterization of COX-2 enhancer by luciferase assay. The diagrams on the top 
show the firefly luciferase reporter constructs driven by various rat COX-2 fragments of -
1234/-1199 (forward and reverse), -1204/-1160 (forward and reverse), -1163/-1131 (forward 
and reverse) in Pgl3-promoter. The luciferase activities from firefly were assayed and the 
relative luciferase activity was obtained by normalizing the firefly luciferase activity of 
constructed plasmids against the control plasmid luciferase activity. The results are 
expressed as mean ± the SEM of six replicated experiments. 
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Figure 5.8. Diagram shows the site-directed mutagenic sites of COX-2 enhancer. Three different mutations were conducted 
separately. From left to right: ΔHOXD8, TTA to GGG; ΔRAF, CGG to ATT; ΔCTCF, CCCT to TTTC 
 
-1234 
 
-1131 
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  Figure 5.9 Characterization of COX-2 enhancer by luciferase assay. The diagrams on the 
top show the firefly luciferase reporter constructs driven by various rat COX-2 fragments that 
contains different mutation sites. Relative location of each mutation site is marked. The 
luciferase activities from firefly were assayed and the relative luciferase activity was obtained 
by normalizing the firefly luciferase activity of constructed plasmids against the control 
plasmid luciferase activity. The results are expressed as mean ± the SEM of six replicated 
experiments. 
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Figure 5.10 Time course of the Arachidonic acid treatment. PC3 cells were grown in 
RPMI-1640 medium and starved with 0.3% FBS supplemented with 1.25mg/mL fatty acid 
free BSA for 48 hours before treatment. Cells were then incubated with 10μg/ μL AA for 
30min, 1h, 2h and 3h to induce COX-2 expression. Values are means ± SEM. *P<0.05 
 
Hours 
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Figure 5.11 Luciferase activities of enhancer constructs (Forward, F; Reverse, R) in 
response to Arachidonic acid. Values are normalized to PGL3-p. The results are 
expressed as mean ± the SEM of six replicated experiments. 
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Table 5.2 Primer sequences used in cloning and sequencing 
COX-2 
(ENSRNOT00000003567) 
Sequences 
-1234 to -1199, +SmaI top, GGG CCATTCATGCCAAGAACGTACGGTTTAATTGAATGT CCC 
bottom, GGG ACATTCAATTAAACCGTACGTTCTTGGCATGAATGG CCC 
-1204 to -1160, +SmaI top, GGG GAATGTTTTAGTTTCCTCATTTTCTTGTTTTACTCGGTTTTTCAC CCC 
bottom, GGG GTGAAAAACCGAGTAAAACAAGAAAATGAGGAAACTAAAACATTC CCC 
-1163 to -1131, +SmaI top, GGG CACTATTCCATCCTCAGATCCCCCTCCCGGGC CCC 
bottom, GGG GCCCGGGAGGGGGATCTGAGGATGGAATAGTG CCC 
-1234, +SacI Forward, ATTATA GAGCTC CCATTCATGCCAAGAACGTACGGT 
-1029, +SacI Reverse, ATTATA GAGCTC ATCCA CTTCT TTCTG AAACA TTGCT TGA 
-906, +SacI Reverse, ATTATA GAGCTC GACTTATTTTTGTCCACGTTTACGTTTACAAG 
-814, +SacI Reverse, ATTATA GAGCTC GGTATTTTCCTCCCTGCTGTTACATAGC       
-1234, +NheI Forward, ATTATAGCTAGCCCATTCATGCCAAGAACGTACGGT 
+30, +NheI Reverse, ATTATAGCTAGCGCGCAGAGCAGCACAGCTCGGAAGAGC 
deltaRAF, cgg to att Forward, TTTAGTTTCCTCATTTTCTTGTTTTACTATTTTTTTCACTATTCCATCCTCAGATCCCC 
Reverse, 
GGGGATCTGAGGATGGAATAGTGAAAAAAATAGTAAAACAAGAAAATGAGGAAACTAAA 
deltaHOXD8, tta to ggg Forward, TCCCATTCATGCCAAGAACGTACGGTGGGATTGAATGTTTTAGTTTCCTCATTTTC 
Reverse, GAAAATGAGGAAACTAAAACATTCAATCCCACCGTACGTTCTTGGCATGAATGGGA 
deltaCTCF, ccct to tttc Forward, CTATTCCATCCTCAGATCCTTTCCCCGGGCTCGAGATCTGCG  
Reverse, CGCAGATCTCGAGCCCGGGGAAAGGATCTGAGGATGGAATAG 
-1533, bisulfite seq Forward, AGAATTAAATTAGTATGTATATGAAGTAAA 
-1109, bisulfite seq Reverse, TTCCCACTATATTTAATATTAACCC 
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